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Colorectal cancer leads to over 50,000 deaths in the United States each year. Many colon cancer 
patients are diagnosed at late stages where surgical options are limited and require chemo- and or 
radiotherapy.  A hallmark of cancer is the accumulation of genetic mutations resulting in 
dysfunction of the apoptotic response, which can lead to reduced sensitivity to chemo- and 
radiotherapy.  Damaged cells can also die through necrosis, previously thought to be an 
unregulated process.  Recent studies have begun to suggest that necrosis is an orderly event that 
occurs in cells when apoptosis is blocked, and kinases, rather than p53, play a critical role in 
activating downstream necrotic machinery.  The high incidence of p53 mutation and apoptotic 
dysfunction in cancer requires development of new treatment strategies, with activation of 
necrosis a potentially beneficial option.  However, little is known about the relationship between 
different forms of cell death and how it is regulated. 
Caspases are cysteine proteases best known to play a pivotal role in the execution of 
apoptosis.  However, recent studies indicate roles beyond apoptosis.  Interestingly, Caspase-8 
inhibits autophagy and necrosis, whereas caspase-3 promotes survival of cancer cells following 
radiation therapy.  In an effort to determine the role of caspase-3 in colon cancer cell survival 
and proliferation, we generated caspase-3 knockout HCT-116 colon cancer cells using 
recombinant adeno-associated virus (AAV)-mediated gene targeting.  Interestingly, we observe 
an unexpected decrease in proliferation and altered mitochondrial morphology in caspase-3 
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knockout cells, compared to wild-type cells.  Furthermore, caspase-3 knockout cells exhibit 
reduced oxidative phosphorylation and increased glutamine dependence.  In addition to altered 
metabolism, caspase-3 knockout cells are more sensitive to DNA damaging agents, including 5-
FU, etoposide and camptothecin due to an increase in programmed necrosis.  This is in stark 
contrast to wild-type cells that die largely via apoptosis.  Having shown that caspase-3 promotes 
survival and proliferation of colon cancer cells and reduces sensitivity to multiple DNA 
damaging agents we hypothesize that targeting its non-apoptotic functions may improve the 
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1.0  COLORECTAL CANCER 
1.1 ABSTRACT 
Colorectal cancer (CRC) is one of the predominant cancers worldwide, annually affecting 1.23 
million new patients, resulting in the death of 500,000 and accounting for 10% of all human 
cancers [1, 2].  In the United States it stands as the fourth most common cancer and the second 
leading cause of cancer related death [3].  The current five year survival rate for all CRC patients 
is 60% with only 6% of metastatic patients, indicating the need for improved therapeutic options 
[4].  
 
1.1.1 Risk factors 
Similar to other cancers, colorectal cancer incidence seems to be intimately tied to both 
environmental and genetic factors. CRC risk increases by age with 80% of patients being 
between the age of 55 and 85 years old. [5-7].  Other common risk factors include excess body 
weight, lack of physical activity and first-degree relatives with CRC (Table 1). 
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Table 1: Colon Cancer Risk Factors 
Colorectal Cancer Risk Factors 
Non-preventable Factors Preventable Factors 
Age older than 50 years High-fat diet 
Previous CRC diagnosis Low consumption of fruits & vegetables 
Polyps Lack of physical activity 
First degree relative with CRC Obesity 
Ulcerative colitis Smoking 
Crohn's disease Alcohol consumption 
 
1.1.2 Evolution of CRC 
Colorectal tumors are found in a number of different forms ranging from benign tumor to invasive 
cancer, with the majority of tumors arising from epithelial tissue.  Newly discovered colorectal tumors 
within a patient are classified as nonneoplastic polyps, neoplastic polyps or cancer.    Upwards of 30% 
of Americans will develop polyps in their lifetime and 70-90% of CRCs arise from adenomatous 
polyps [8].  Roughly 30% of all polyps are hyperplastic and at no risk for future malignancy.  
However, others are adenomatous and considered premalignant [9].  Half of polyps greater than 2 cm 
in diameter ultimately advance to malignant tumors.  Currently the best method for polyp treatment is 
surgical removal [10].     
1.1.3 Multiple gene mutations lead to CRC 
The advancement of normal epithelial tissue to CRC is associated with multiple molecular events.  
Although CRC can be caused by a single gene mutation, it is predominately initiated as the result of 
multiple genetic mutations (average of 5-7) in genes that regulate cell cycle and/or apoptosis including 
tumor suppressor, oncogenes and genes associated with repair/stability [11-13].  Tumor suppressor 
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mutations are the most common mutations found in hereditary CRC and are the causative mutations 
behind both Familial Adenomatous Polyposis (FAP) and Juvenile Polyposis Syndrome (JPS).  
Mutation in stability genes, including mismatch repair genes are another large contributor to hereditary 
CRC and are the causative mutation behind Lynch syndrome.  Table 2 summaries current knowledge 
of genetic mutations found in CRC and their corresponding diseases [11, 12].   
 
Table 2: Known gene mutations in CRC 







Suppressor FAP Dominant Colon, intestine 
AXIN2 
Tumor 
Suppressor Attenuated polyposis Dominant Colon  
TP53 
Tumor 
Suppressor Li-Fraumeni Dominant Multiple 
STK11 
Tumor 
Suppressor Peutz-Jeghers Dominant Multiple 
PTEN 
Tumor 
Suppressor Cowden Dominant Multiple 
BMPR1A 
Tumor 
Suppressor Juvenile polyposis Dominant Gastrointestinal 
SMAD4 
Tumor 
Suppressor Lynch Dominant Gastrointestinal 
MLH1 Repair/Stability Lynch Dominant Multiple 
MSH2 Repair/Stability Lynch Dominant Multiple 
MSH6 Repair/Stability Lynch Dominant Multiple 
PMS2 Repair/Stability Lynch Dominant Multiple 
EPCAM Repair/Stability Lynch Dominant Multiple 
MYH Repair/Stability Attenuated polyposis Recessive Colon 
BLM Repair/Stability Bloom Recessive Multiple 
KIT Oncogene Familial GIST - GIST 
PDGFRA Oncogene Familial GIST - GIST 
Adapted from http://www.cancer.gov/cancertopics/pdq/genetics/colorectal/healthprofessional/page2 
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1.1.4 Prevention and treatment 
Observational studies of the average risk population has shown that the use of multiple drugs 
including Non-steroidal Anti-inflammatory Drugs (NSAIDs), estrogens, folic acid and calcium 
might help prevent the development of CRC [10, 14].  Additional approaches to reduce risk of 
developing CRC include eating a low fat diet, exercising regularly and limiting alcohol/tobacco 
use [6, 10].  In the event of CRC diagnosis there are currently six standard treatments widely 
used.  The first line of therapeutic intervention is surgery including both local excision and 
surgical resection of the colon.  In addition to surgical removal of malignant tissue, patients are 
concurrently treated with radiofrequency ablation, cryosurgery, chemotherapy, radiation therapy 
or targeted therapies.  Historically, chemotherapy has been the most commonly used approach.  
Currently there are 28 CRC approved chemotherapeutic drugs.  Targeted therapy has gained 
significant momentum in recent years due to optimism that it might provide greater therapeutic 
response with fewer side effects than are generally associated with chemotherapy.  Currently 
monoclonal antibodies and Vascular Endothelial Growth Factor (VEGF) inhibitors are the only 
FDA approved targeted therapies for CRC.  Unfortunately while targeted therapies have shown 
great efficacy in initial response, a large proportion of patients will develop resistance within two 
years of initial treatment.  Despite our best efforts, the current five year survival rate for all 
colorectal cancer patients is 60% with 6% of metastatic patients surviving that period.  Clearly 
new therapeutic approaches are urgently needed [10, 11].   
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1.2 MOLECULAR ALTERATIONS IN COLORECTAL CANCER 
The hallmarks of cancer are composed of eight biological abnormalities acquired during the 
multistep development of malignant tumors.  They include: sustained proliferative signaling, 
evasion of growth suppression signaling, cell death resistance, acquired replication immortality, 
increased angiogenesis, reprogramming of energy metabolism, evasion of immune destruction 
and activation of invasion and metastasis [15].  The underlining of these hallmarks is genetic 
instability which allows for the acquisition of advantageous phenotypes and inflammation which 
fosters multiple hallmark functions.   
1.2.1 Cancer cells demonstrate unregulated proliferation 
Cell proliferation is a vital function for mammals and is required for normal development, repair 
and general maintenance of tissue.  However, uncontrolled cell proliferation is a major cause 
behind tumorigenesis.  Progression of normal tissue to malignant tumor is a stepwise process 
composed of acquisition of genetic mutations leading to altered phenotype.  In the context of 
CRC, one of the most common first steps towards malignancy is loss of Wingless-type MMTV 
Integration Site Family (Wnt) signaling regulation.  The Wnt/β-catenin pathway is responsible 
for directing growth and patterning during embryonic development.  Additionally, the pathway 
directs postembryonic regulation of stem cell populations in the intestine [16].  A common 
mutation acquired by CRC patients is inactivation of the Adenomatous Polyposis Coli (APC) 
tumor suppressor.  APC is responsible for down-regulation of transcriptional activation mediated 
by the β-catenin and T Cell Transcription Factor 4 (TCF4).  Mutant APC is defective in this 
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activity resulting in unchecked activation of β-catenin signaling and increased cell proliferation 
(Figure 1) [17].   
V-Ki-ras2 Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) is a GTPase 
responsible for down regulating the v-raf-1 Murine Leukemia Viral Oncogene/Mitogen-activated 
Protein Kinase (RAF/MAPK) proliferative pathways (Figure 1).  A single amino acid 
substitution most commonly occurring in codons 12 and 13 is responsible for constitutive 
activation. The transformed protein that results is implicated in various malignancies, including 
lung adenocarcinoma, mucinous adenoma, ductal carcinoma of the pancreas and colorectal 
carcinoma [18-21].  Current estimates suggest that KRAS is mutated in 35-45% of CRCs [22].  
In addition to increased cell proliferation KRAS mutation is an indicator of resistance to 
Epithelial Growth Factor Receptor (EGFR) based therapies [20].   
 Transforming Growth Factor Beta (TGFβ) is a member of the transforming growth factor 
family of cytokines which are multifunctional peptides that regulate proliferation, adhesion, 
differentiation, migration and other functions in a large number of cell types.  Many cells contain 
TGFβ receptors and ligation of the receptor is able to both positively and negatively regulate 
many other growth factors [23].  In the context of CRC, TGFβ is a potent inhibitor of epithelial 
cell growth.  CRC cells with high rates of microsatellite instability were found to harbor 
mutations in TGFβ leading to its inability to inhibit cell growth (Figure 1) [24-26].   
 Tumor Protein p53 (p53) is one of the most commonly mutated proteins in all 
malignancies [27, 28].  p53 is stabilized in response to a number of stimuli including DNA 
damage, hypoxia, viral infection or oncogenic activation.  Activation of p53 results in a number 
of diverse manners including cell cycle arrest, apoptosis, senescence, differentiation and 
antiangiogenesis.  p53 activity is highly regulated by post translational modifications including 
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phosphorylation, dephosphorylation and acteylation.  Active p53 signals a number of 
downstream proteins including Cyclin-dependent Kinase Inhibitor 1 (p21), Growth Arrest and 
DNA-damage-inducible Protein (GADD45), 14-3-3σ, BCL2-associated X Protein (Bax), TNF 
Receptor Superfamily Member 6 (Fas), Death Receptor 5 (DR5), Spermatogenic Leucine Zipper 
1 (Tsp1), Insulin-like Growth Factor Binding Protein 3 (IGF-BP3) and others [29].  
Approximately half of all CRCs show p53 gene mutations with greater frequencies in distal 
colon and rectal tumors and lower frequencies in proximal tumors and tumors harboring 
microsatellite instability (Figure 1) [30].  Furthermore, mutated p53 is highly overexpressed in 
CRC tumors [31].  Multiple point mutations have been documented and a patient’s therapeutic 
response is strongly tied to their mutation status.  Specifically, point mutations in the conserved 
domains of p53 were inherently more aggressive than mutations outside of them and mutations 
of codon 175 were highly aggressive [32, 33]. 
 The final phase in CRC progression is metastasis.  It has become increasingly clear that 
there are a number of molecular alterations that lead tumors to become increasingly invasive 
including increased matrix metalloproteinase leading to loss of basement membrane and 
decreased epithelial gene expression leading to epithelial-mesenchymal transition (EMT) (Figure 
1) [34-36].  Progression from normal epithelium to localized colorectal carcinoma and final 
metastatic disease is a stepwise process composed of acquired genetic alterations leading to 
altered cell signaling often resulting in activation of multiple pathways that signal increased 
proliferation.  Therapeutic targeting of such pathways is a key theme in current chemotherapeutic 




Figure 1: Progression of colorectal cancer 
Known pathway alteration in CRC and resulting molecular consequences.  APC - adenomatous 
polyposis coli, CTGF - connective tissue growth factor, TSP1 -thrombospondin 1, EGFR - epidermal growth 
factor receptor, mTOR - mechanistic target of rapamycin, PTEN - phosphatase and tensin homolog, DCC - 
deleted in colorectal carcinoma, TGFβ R1/2 - transforming growth factor, beta receptor 1/2, CASP3 - caspase 
3, SIRT1 - sirtuin 1, CDK4,6 - cyclin-dependent kinase 4,6, ECM - extracellular matrix, EMT - epithelial--
mesenchymal transition, ICAMs - intercellular adhesive molecules, miR – microRNA, TIMP3 - tissue 
inhibitor of metalloproteinase 3, PDCD4 - programmed cell death 4, RECK - reversion-inducing-cysteine-
rich protein with kazal motifs, uPAR - plasminogen activator, urokinase receptor, MMPs - matrix 
metallopeptidases, ZEB1/2 - zinc-finger E-box binding homeobox 1).   Adapted from Slaby et al. Molecular 
Cancer 2009 8:102   doi: 10.1186/1476-4598-8-102. 
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1.2.2 Cancer cells have increased metabolic demands 
Otto Warburg was the first to describe a phenomenon in which cancer cells are able to suppress 
oxidative phosphorylation and increase glycolysis [37].  This alteration in metabolic processes 
allows cells to continually proliferate in situations where oxygen might be depleted.  However, 
cancer cells often show increased glycolysis even in the presence of adequate oxygen levels [38-
40].  Furthermore, tumor related metabolic abnormalities are not limited to altered balance 
between glycolysis and oxidative phosphorylation [41].  While p53 and V-myc 
Myelocytomatosis Viral Oncogene Homolog (MYC) have long been regarded as master 
regulators of metabolism, recent studies have uncovered a number of other proteins including 
Isocitrate Dehydrogenase I (IDH1), Pyruvate Kinase Muscle Form 2 (PKM2), Fumurate 
Hydratase (FH) and Succinate Dehydrogenase (SDH) that, when mutated, have the capability of 
inducing tumorigenesis [41-45].  With these advancements it is becoming increasingly clear that 
altered cellular metabolism is sufficient in itself to induce cancer [41].   
As a consequence of increased glycolysis cancer cells often have higher dependence upon 
glucose to sustain continual proliferation [41, 46].  Interestingly, many cancer lines demonstrate 
glutamine addiction [47].  This is puzzling due to the fact that glutamine is not an essential 
amino acid and can be synthesized from glucose.  Recent evidence suggests that glutamine 
addiction has more to do with glutamine’s ability to activate Target of Rapamycin (TOR) and 
maintain mitochondrial membrane potential rather than serve as a nitrogen donor for protein 
synthesis [47].   
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1.2.3 Mitochondria are often altered in cancer 
Mitochondria have multiple roles within the cell including generation of Adenosine-triphosphate 
(ATP), production and regulation of reactive oxygen species (ROS) and maintenance of 
intracellular calcium levels.  In line with the observed increase in aerobic glycolysis, many 
cancer cells have been shown as having defective mitochondria.  Tumor mitochondria are often 
relatively small, lack cristae, and are deficient in the β-F1 subunit of ATP synthase [48, 49].  
Frequently mitochondrial DNA is mutated in carcinomas, including: breast, colon, 
hepatocellular, pancreatic, prostate, lung, renal, thyroid and brain among others [50].  It is still 
unclear whether this is a consequence of malignancy or a driving force behind it [51, 52].  In 
addition to increased glycolysis, faulty mitochondria drive tumorigenesis by activation of 
downstream proliferative pathways including the V-Akt Murine Thymoma Viral Oncogene 
Homolog 1 (AKT) pathway.  Defects in mitochondrial respiration cause increased levels of 
NADH, which can subsequently inactivate Phosphatase and Tensin Homologue (PTEN), a lipid 
phosphatase that is vital to inhibition of Phosphoinositide-3-kinase (PI3K)/AKT signaling [53, 
54].   
1.2.4 Significance 
Identification of highly proliferative cells has long been a therapeutic approach for cancer 
patients.  While this strategy has shown some success, it inevitably also affects highly 
proliferative off target cells of the intestine, hematopoietic system, mucus membranes and hair 
follicles.  Identification of altered metabolic strategies implored by cancer cells may provide an 
additional layer of therapeutic specificity.  Manipulation of glucose and glutamine serum levels 
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has the potential to be lethal to cancerous cells but not normal tissue that would be sustained by 
increased levels of oxidative phosphorylation.  Furthermore, identification of potentially lethal 
mitochondrial abnormalities specific to cancerous cells would provide additional targets for the 
next generation of targeted therapies.   
1.3 CELL DEATH IN COLORECTAL CANCER  
1.3.1 Apoptosis 
Apoptosis, also known as type I cell death is initiated and executed by a series of well-ordered 
biochemical events and regulated by complex signaling networks.  There are two major apoptotic 
pathways, termed as the extrinsic and intrinsic pathways, which are responsible for processing 
stress signals and executing cell demise [55, 56]. There is significant cross-talk in many 
situations among these two pathways, but each pathway has distinct regulatory processes.  
 
1.3.2 Extrinsic pathway 
The extrinsic apoptotic pathway was first found to be used by immune cells to kill infected or 
damaged cells, and subsequently shown to operate in many cell types [57].  This pathway is 
engaged upon binding of proapoptotic ligands to cell surface death receptors of the Tumor 
Necrosis Factor Receptor (TNFR) family.  All death receptors contain a cysteine-rich 
extracellular domain, which is responsible for ligand binding, and an intracellular death domain 
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for transmitting signals through the recruitment of effectors.  Proapoptotic ligands belong to the 
extended cytokine Tumor Necrosis Factor (TNF) super family, and are either present on the cell 
surface or secreted into the extracellular space [55, 56].  Upon binding of proapoptotic ligands to 
their respective receptors, each receptor can independently form a Death-inducing Signaling 
Complex (DISC) by recruiting the adapter protein Fas (TNFRSF6)-associated Via Death Domain 
(FADD), along with pro-caspase-8 and pro-caspase-10 [56].  FADD recruitment and DISC 
formation lead to proximity-induced processing and activation of caspase-8 and caspase-10, and 
their release into the cytoplasm triggers subsequent activation of effecter caspases to execute 
apoptosis. 
 
1.3.3 Intrinsic pathway 
The intrinsic apoptotic pathway is triggered by stresses such as DNA damage, deregulated 
oncogenes or nutrient/growth factor deprivation, and is largely regulated by the B-cell 
CLL/lymphoma 2 (Bcl-2) family of proteins and mitochondria [58, 59].  For example, following 
DNA damage and p53 activation, death signals are transmitted to Bcl-2 Homology Domain 3 
(BH3)-only proteins to allow for the activation of BCL2-associated X Protein (Bax) and BCL2-
antagonist/killer 1 (Bak), which leads to mitochondrial outer membrane permeabilization 
(MOMP) [60-62] and release of several mitochondrial apoptogenic proteins, including 
cytochrome c, Secondary Mitochondrial Activator of Cytochrome c (SMAC/Diablo), HtrA 
Serine Peptidase 2 (Omi/HtrA2), Apoptosis-inducing Factor (AIF), and Endonuclease G 
(EndoG)  [63].  The release of cytochrome c promotes the assembly of the apoptosome and 
subsequent activation of caspase-9 [63].  Additionally, SMAC/Diablo and HtrA2/Omi facilitate 
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apoptosis by binding to Inhibitor of Apoptosis Proteins (IAPs) and relieving their inhibition of 
caspases [64, 65].  The release of AIF and EndoG promotes DNA degradation [66, 67].  Notably, 
in some cells where there are low levels of DISC, caspase-8-dependent cleavage of the BH3-only 
protein BH3-interacting Domain Death Agonist (Bid) generates truncated Bid (tBid) to amply 
apoptotic signaling via the mitochondria [68, 69]. 
1.3.4 Bcl-2 family proteins 
The Bcl-2 family proteins are central regulators of caspase activation and their competing 
factions of proapoptotic and antiapoptotic members dictate a cell’s decision to live or die.  The 
BH3 family is composed of both antiapoptotic (Bcl-2, BCL2-associated Agonist of Cell Death 
(Bcl-XL), Myeloid Cell Leukemia Sequence 1 (MCL1) and others) and proapoptotic (Bax, Bid, 
Bak, BCL2-related Ovarian Killer (Bok), BCL2-associated Agonist of Cell Death (Bad), BCL2-
Like 11 (Bim), Bcl2 Modifying Factor (Bmf), BCL2-interacting Killer (Bik), Phorbol-12-
myristate-13-acetate-induced Protein 1 (Noxa), p53-upregulated Modulator of Apoptosis 
(PUMA) and others) proteins that govern mitochondrial membrane potential [70, 71].   
1.3.5 Caspase activation 
Both the mitochondrial dependent intrinsic and death receptor dependent extrinsic apoptotic 
pathways lead to the activation of initiator caspases (caspases 2, 8, 9 and 10) that will in turn 
activate executioner caspases (caspases 3, 6 and 7) (Figure 2) [72-74].  Caspases belong to a 
family of conserved aspartate-specific cysteine proteases that are initially synthesized as 
zymogens, also known as procaspases.  A distinct difference between initiator and executioner 
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caspases lies in their activation.  Initiator procaspases are stable monomers in the cell and upon 
dimerization gain enzymatic activity.  Further chain cleavage of dimerized initiator caspases aids 
in stabilization of the active site but doesn’t affect activity.  In contrast, the executioner caspases 
have been shown to be stable dimers that do not gain enzymatic activity until after cleavage of 
the interdomain linker which allows for translocation of the activation loop facilitating formation 
of the active site (Figure 2) [75-78].   
Upon initiation of the intrinsic apoptotic response, cytochrome c is released from the 
mitochondria.  Its release prompts activation of Apoptotic Peptidase Activating Factor 1 (APAF-
1) which binds to and initiates cleavage/activation of caspase-9.  Caspase-9 then activates 
caspases 3 and 7.  Caspase-3 in turn activates caspase-6 which then activates caspases 8 and 10 
[79].  Studies have also shown a reduction in caspase-9 activity in cells depleted of caspase-3 
suggesting that it feeds back to caspase-9 and increases activity once active itself [79, 80].   
Caspase-3 has been shown to play an important role in the initiation and amplification of 
extrinsic apoptosis in human T lymphocytes.  Prior to activation of Fas, the zymogen form as 
well as mature caspase-3 was found to be co-localized with FADD and caspase-8 in lipid rafts at 
the base of Fas.  This association was amplified following activation of Fas with Fas ligand (Fas-
L).  In the presence of Bcl-2 over-expression caspase-3 maturation was prevented resulting in 
accumulation of the partially processed p20 fragment.  It has been suggested that in the presence 
of Bcl-2, X-linked Inhibitor of Apoptosis (XIAP) is able to bind to the p20 fragment of caspase-3 
and prevent removal of its prodomain.  Lack of caspase-3 activation resulted in reduced caspase-
8 activation and a reduction in apoptosis [81]. 
While caspase-3 has recently been shown to have roles in brain development, 
cytoskeleton remodeling, T cell activation and stem cell differentiation, among others, all 
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functions are dependent upon its enzymatic activity [82-86].  There currently is little knowledge 
of any non-enzymatic activities performed by caspase-3. 
 
 
Figure 2: Known human caspases 
Caspases are initially found in uncleaved “zymogen” form and have known roles in apoptosis and the 
inflammatory response.  Caspases 2, 8, 9 and 10 are known as initiator caspases.  Caspases 3, 6 and 7 are 
executioner caspases.  DED= Death Effector Domain. CARD = Caspase Activation and Recruitment Domain.  
Numbers denote amino acid sequence. 
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1.3.6 Inhibitors of apoptosis 
The inhibitor of apoptosis family of proteins was originally identified in model organisms.  
Endogenous inhibitors of IAPs such as SMAC and HrtA2  can directly bind to a conserved 
Baculovirus Interacting Repeat (BIR) within IAPs.  The binding of SMAC to IAPs is mediated 
through a conserved tetrapeptide.  Cumulative evidence in the last decade using biochemical, 
molecular and cellular, pharmacological, structural biology approaches and genetically modified 
model systems has revealed a multitude of IAP functions in cell death, survival, proliferation and 
immunity.  Furthermore, several IAPs play a key role in regulating Nuclear Factor of Kappa 
Light Polypeptide Gene Enhancer in B-cells (NF-кB) activation and non-apoptotic cell death.  
Overexpression and genetic alterations of IAPs, as well as reduced expression of their 
endogenous inhibitors have been reported in solid tumors and hematological malignancies [87, 
88].  In rare cases, loss of IAPs is associated with the development of certain types of 
hematological malignancies, suggesting a potential role as a tumor suppressor [89]. 
Agents targeting IAPs have been developed, with the most promising class being small 
molecules mimicking the IAP binding domain in SMAC, also known as SMAC mimetics.  These 
compounds have limited toxicity to cancer cells as a single agent, while synergizing with 
different classes of anti-cancer agents in a wide array of cancer cell types.   The use of SMAC 
mimetics has helped elucidate signaling functions of IAPs, particularly cIAP1 and cIAP2, 




APAF-1 is a key protein component of the intrinsic apoptotic response.  In response to 
genotoxic stress, cytochrome c is released from the mitochondria.  In the presence of cytochrome 
c and dATP, APAF-1 oligomerization occurs and the Caspase recruitment domains (CARDs) of 
APAF-1 and caspase-9 interact with each other to form a CARD-CARD disk which can then act 
as an asymmetrical proteolysis machine [90].  Two forms of the apoptosome have been 
described, a 700 kDa form and a 1.4 MDa form.  The smaller 700 kDa form appears to be the 
first to form following activation of the apoptotic response and has a greater capacity for 
activating executioner caspases [91].    
1.3.8 Death-inducing signaling complex 
The DISC, also known as Complex-I, is critical for initiation of death receptor-mediated 
apoptosis.  After FAS ligation, TNFRSF1A-associated via Death Domain (TRADD) is recruited 
to the base of the receptor followed by FADD, caspase-8, RIP1 and CASP8 and FADD-like 
Apoptosis Regulator (cFLIP), all of which complex to form the DISC (Figure 3).  Complete 
formation of the DISC leads to activation of caspase-8 and subsequent downstream cleavage and 
activation of executioner caspase-3 and Bid [92].   
1.3.9 PIDDosome 
The PIDDosome is a relatively small (500kDa) apoptotic cell death complex that forms in 
response to genotoxic stress.  It is comprised of the core components; caspase-2, p53-induced 
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Death Domain Protein (PIDD), and CASP2 and RIPK1 Domain Containing Adaptor With Death 
Domain (RAIDD) (Figure 4) [93].  PIDDosome activity has been shown to be p53 dependent 
upon treatment with DNA damaging agents, including 5-FU.  Interestingly cell death is absent in 
p53 null cancer cells, but the PIDDosome still forms following 5-FU treatment [94].  
1.3.10 Autophagy 
Autophagy is an intracellular degradation system that is found ubiquitously in eukaryotes.  It is 
responsible for the degradation of long-lived proteins and certain organelles.  Cytoplasmic 
components, including organelles are sequestered into double membrane autophagosomes which 
subsequently fuse with lysosomes where their contents are degraded.  Autophagy has been 
implicated in numerous physiological processes including protein and organelle turnover, 
starvation response, cellular differentiation, cell death (type II) and pathogenesis [95].   
1.3.11 Necrosis 
Until recently necrosis (type III cell death) was thought of as a disorganized last resort for cells 
unable to initiate apoptosis, autophagy or another preferred method of death.  It has become 
increasingly evident that this is incorrect and, similar to apoptosis, necrosis is a highly ordered 
process comprised of multiple intracellular pathways capable of initiating it [96, 97].   
The first indication that necrosis might be regulated came in 1988 when it was noted that 
distinct cell types died differently in response to the same trigger, TNF.   Certain cell types 
exhibited the traditional apoptotic phenotype, others showed a “balloon-like” morphology 
without nuclear disintegration indicative of necrosis and others exhibited characteristics of both 
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avenues of cell death [98, 99].    This led to the belief that necrosis was not solely induced in 
situations where apoptosis was inhibited.  In the decades since this first observation there have 
been a number of discoveries that have helped outline the induction of programmed necrosis 
(often referred to as necroptosis).  Known activators of necrosis include the receptor-like protein 
kinases, Receptor (TNFRSF)-interacting Serine-threonine Kinase 1 (RIP1) and Receptor 
(TNFRSF)-interacting Serine-threonine Kinase 3 (RIP3) [100-104], TNFR [98], reactive oxygen 
species [105-107], Bcl2 family members [108], caspase inhibitors [109], ubiquitin E3 ligases, 
deubiquitylating enzymes [108, 110], bioenergetic reactions [104, 111], poly (ADP-ribose) 
polymerase (PARP) [112], the mitochondrial permeability transition pore complex [113-115], 
lysosomal membrane permeabilization [116, 117] and lysosomal, mitochondrial and cytosolic 
hydrolases [99, 116-118]  
 
1.3.12 Induction of necrosis occurs through death receptors and pathogen recognition 
receptors. 
Initiation of necrosis can be triggered by ligation of a number of death receptors including 
FAS/CD95 [119], TNFR1 [98, 109], TNFR2 [120], TNF-related apoptosis-inducing ligand 
receptor 1 (TRAIL1) [121] and TRAIL2 [121].  All of these death receptors are also able to 
induce apoptosis and do so preferentially.  In the presence of transcriptional inhibition or caspase 
inhibition by cIAP or exogenous caspase inhibitors, death receptors will resort to activation of 
necrosis [99, 122].  Additionally, recent evidence has demonstrated the ability of pathogen 
recognition receptors (PRRs) to initiate necrosis.  Known PRRs include Toll-like receptors, 
NOD-like receptors and retinoic acid-inducible gene I-like receptors, all of which are expressed 
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by cells of the innate immune system to identify pathogen-associated molecular patterns 
(PAMPs) [123].  Viral double stranded RNA has been shown to induce necrosis mediated 
through PRRs in a number of cell types including Jurkat T Lymphocytes and murine 
fibrosarcoma L929 cells [124].   
1.3.13 Receptor interacting protein kinase 1 
Receptor-interacting protein kinase-1 was the first kinase linked to programmed necrosis [125].  
Since its initial discovery RIP1 has been shown to be quite ever-present, found in all organ 
systems with roles in cell survival, apoptosis and programmed necrosis.  In unstressed cancer 
cells RIP1 is found in the cytosol.  Upon cellular stress and stimulation of TNFR1, RIP1 is 
bound and polyubiquitinated by THF receptor associated factor 2 (TRAF2) at K377 with lysine-
63 linked ubiquitin.  K63-linked polyubiquitination of RIP1 leads to its binding with the death 
receptor TNF and association with Complex-I which contains multiple adaptor proteins 
including NF-kappa-B essential modulator (NEMO), TGF-beta activated kinase 1/MAP3K7 
binding protein 1 (TAB1), TGF-beta activated kinase 2/MAP3K7 binding protein 2 (TAB2) and 
Nuclear receptor subfamily 2 group C member 2 (TAK1).  Association of Complex I induces 
rapid activation of NF-κB with subsequent activation of antiapoptotic proteins including c-FLIP 
and IAPs (Figure 3).  Furthermore Complex-I mediates the activation of prosurvival MAPK 
proteins including Mitogen-activated Protein Kinase 14 (p38), MAPK, c-Jun N-terminal Kinase 
(JNK) and Extracellular-signal-regulated Kinase (ERK) [125-132].   
RIP1 activation of NF-κB is a highly regulated process that can be inhibited at multiple 
levels.  K63-linked polyubiquitinated RIP1 can be bound to and inhibited by Cylindromatosis 
(CYLD).   Additionally, the K63-linked ubiquitin can be removed by TNFAIP3 Interacting 
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Protein 2 (A20) which then promotes K48-linked polyubiquitination at K377 which leads to 
RIP1 degradation by the 26S proteasome.  Furthermore, in the presence of high levels of cIAP 1 
or 2, RIP1 is polyubiquitinated by K48-linked ubiquitin, once again leading to its degradation by 
the 26S proteasome.   
In the presence of prolonged cellular stress, cell survival is negated and cell death is 
induced.  RIP1 has been shown to be an indispensable component of multiple cell death 
complexes including Complex-II (DISC), Complex-IIb (Necrosome) and the Ripoptosome 




Figure 3: RIP1 activation and downstream pathway activation 
 
1.3.14 Receptor interacting protein kinase 3 
RIP3 is a member of the receptor-interacting protein family of serine/threonine protein kinases 
and contains a c-terminal domain that is unique from other RIP family members.  It is primarily 
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localized to the cytoplasm in an inactive conformation.  In response to ligation of TNFR, RIP3 
can act in a similar fashion as RIP1 and induce apoptosis as well as activate the NF-κB signaling 
although to a lesser degree than RIP1 [133].  In addition to prosurvival and proapoptotic 
functions, RIP3 is an essential component of necrotic death.  Upon induction of necrosis, RIP3 
interacts with and phosphorylates RIP1 to form the necrosome [134].  RIP3 also binds to and 
enhances the activity of metabolic enzymes including Glutamate-ammonia Ligase (GLUL), 
Glutamate Dehydrogenase 1 (GLUD1) and Phosphorylase Glycogen Liver (PYGL).  GLUL, 
GLUD1 and PYGL will in turn stimulate the oxidative phosphorylation and the tricarboxylic 
acid cycle (TCA) cycle leading to increased ROS production and an amplification of the necrotic 
response [104].   
 
1.3.15 Reactive oxygen species 
Oxygen derived species including superoxide radical, hydrogen peroxide, single oxygen 
and hydroxyl radical are well known to be cytotoxic and have been implicated in the etiology of 
a range of human diseases including cancer.  Oxidative damage to cellular DNA can lead to 
mutations and aid in the initiation and progression from normal tissue to malignancy.  Elevated 
levels of ROS and reduced levels of ROS scavengers and antioxidants have been identified in a 
number of human cancers [135].  Furthermore, there is solid evidence that cancer cells utilize 
ROS signaling to drive proliferation and other events for tumor progression [136].  However, 
cells have a threshold for elevated ROS levels and when it is met, apoptosis is induced [137].  
This leaves cancer cells with elevated basal ROS levels vulnerable to chemotherapeutic agents 
that further augment ROS generation or that weakens antioxidant defenses of the cell [135].   
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Several independent studies have outlined the role of mitochondria-produced ROS in 
necrosis of L929 fibrosarcoma cells induced by TNFα [138, 139].  Elevated levels of ROS lead 
to inactivation of caspases which inhibits apoptosis leading to increased ROS and a perpetuation 
of the cycle [140].  After enough cellular damage, cells revert to necrotic death.  ROS have also 
been implemented in dsRNA induced necrotic death [124, 141].   
1.3.16 Necrosome 
Complex-IIb, also known as the necrosome, is a large cell death complex composed of TRADD, 
FADD, Caspase-8, RIP1 and RIP3 (Figure 4). Formation of the necrosome is dependent upon the 
presence of both RIP1 and RIP3 and does not form in the absence of either component.  RIP1 
ubiquitination (both K63-linked and K48-linked) has also been shown to inhibit formation of the 
necrosome.  Upon induction of necrosis by death receptor ligation, RIP1 and RIP3 interact 
through RIP homotypic interaction motifs (RHIMs) and initiate both auto and mutual 
phosphorylation at S161 (RIP1) and S199 (RIP3) [142, 143].  Phosphorylation leads to activation 
of both proteins and signaling of downstream targets including Mixed Lineage Kinase Domain-
Like (MLKL) and Phosphoglycerate Mutase Family Member 5 (PGAM5) [96, 97]. 
1.3.17 Ripoptosome 
The Ripoptosome is a 2MDa cell death complex that is unique in its ability to induce both 
caspase-8 mediated apoptosis and caspase-independent necrosis depending upon the 
presence/absence of certain proteins [144].  Discovered in 2011, the Ripoptosome is composed 
of the core components RIP1, FADD, and caspase-8 (Figure 4) [144, 145].  It forms in the 
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response to depletion of inhibitor of apoptosis proteins (XIAP, cIAP1 and cIAP2) as a result of 
genotoxic stress or use of SMAC mimetics.  Unlike the necrosome, the Ripoptosome does not 
form in response to death receptor (TNFR, FAS, and TRAIL) or mitochondrial pathway 
stimulation [144].  Ripoptosome assembly is intimately linked to the kinase activity of RIP1 and 
is negatively regulated by cIAP mediated ubiquitination and subsequent degradation of RIP1 








A common characteristic of cancer is genetic abnormalities leading to reduced ability to 
initiate apoptosis.  A better understanding of all the avenues in which cell death can be initiated 
and the protein complexes involved in each respective pathway will provide potential new 
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targets and approaches for tumors resistant to apoptosis.  Although initially thought of as not 
ideal, autophagy and necrosis activation might be key mechanisms behind future 
chemotherapeutic options.   
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2.0  LOSS OF CASPASE-3 LEADS TO IMPAIRED GROWTH AND ALTERED 
BIOENERGENTICS IN COLORECTAL CANCER CELLS 
2.1 ABSTRACT 
A hallmark of cancer is the ability to proliferate uncontrollably.  In the 1930s Otto Warburg 
discovered that cancer cell metabolism is unique from normal cells and utilizes glycolysis at a 
much higher rate.  It was initially thought that this altered metabolism was the driving force 
behind the rapid proliferation of cancer cells.  Emerging evidence indicates that an acidic 
environment resulting from increased glycolysis is detrimental to normal cells but does not affect 
cancer cells.  Furthermore, glycolysis produces less reactive oxygen species compared to 
oxidative phosphorylation.  While advantages of increased glycolysis have been identified, the 
mechanisms underlying altered energy metabolism in cancer cells are still unclear.     
Caspases are cysteine proteases best known to play a pivotal role in the execution of 
apoptosis.  In an effort to determine the role of caspase-3 in colon cancer cell survival and 
proliferation, we generated a caspase-3 knockout human colorectal cancer HCT116 cell line 
using recombinant adeno-associated virus (AAV)-mediated gene targeting.  Our studies showed 
an unexpected decrease in growth and colony formation in caspase-3 knockout cells without 
increased cell death.  The defects in cell proliferation and long-term growth were rescued by full 
length but not catalytically dead caspase-3.  Furthermore, caspase-3 knockout cells were 
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significantly smaller, had abnormally shaped mitochondria, and showed increased production of 
reactive oxygen species compared to their normal counterparts.  Stable knockdown of caspase-3 
in HCT116 cells recapitulated the altered growth and increased ROS production.  We also found 
a near -complete loss of mitofusin-2 expression in caspase-3 knockout cells.  The role of 
caspase-3 in altering cancer cell growth was investigated in xenograft and cell culture models.  In 
summary, our data demonstrate a novel role of caspase-3 in cell proliferation and bioenergetics, 




Cell proliferation is a vital function for mammals and is required for development, repair, 
and general maintenance of tissue.  However, uncontrolled cellular proliferation ultimately leads 
to cancer, a phenomenon caused by the accumulation of genetic mutations over time.  Current 
therapeutic strategies attempt to curtail cancer development by preferentially targeting their 
ability to rapidly proliferate. .   
Otto Warburg was the first to describe a phenomenon in which cancer cells are able to 
suppress oxidative phosphorylation and increase glycolysis [37].  This alteration in metabolic 
processes allows cells to continually proliferate in situations where oxygen might be depleted.  
As a consequence of increased glycolysis, cancer cells often have a higher dependence upon 
glucose to sustain continual proliferation.  Additionally, cancer cells often show an addiction to 
glutamine, a paradoxical phenomenon in light of the fact that glutamine is a nonessential amino 
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acid that can be synthesized from glucose [47].  The current understanding of glutamine 
addiction suggests that it is critical for use as a nitrogen donor in nucleotide and amino acid 
biosynthesis as well as a regulator of (target of rapamycin) TOR activation [47].    
Mitochondria have multiple roles within the cell, including the generation of ATP, the 
production and regulation of reactive oxygen species (ROS), and the maintenance of intracellular 
calcium levels. In addition to metabolic processes, mitochondria play a vital role in the activation 
and amplification of the apoptotic response [53].  It has been hypothesized that the altered 
mitochondrial function witnessed in cancer cells leads to a reduced apoptotic response and 
increased malignancy.    
Caspase-3 is generally associated with cell death pathways rather than mitochondria and 
cancer cell metabolism.  In light of this, we were surprised to find that caspase-3-null colon 
cancer cells showed reduced proliferation, altered mitochondrial morphology, and hindered 
oxidative phosphorylation when compared to wild-type (WT) cells.  Identifying the role caspase-
3 plays in these processes might prove beneficial in restoring mitochondria to a pre-malignant 
state.   
2.3 MATERIALS AND METHODS 
2.3.1 Cell Culture and Drug Treatment  
Human colorectal cancer cell lines, including HCT116, RKO, and embryonic kidney 293T cells 
were obtained from the American Type Culture Collection (Manassas, VA, USA). RKO, 
HCT116, and derivative cell lines were cultured in McCoy’s 5A modified media (Life 
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Technologies) at 37ºC/5% CO2.  293T cells were maintained in DMEM (Life Technologies) 
media at 37ºC/5% CO2.    All media was supplemented with 10% FBS and 1% Penicillin-
Streptomycin solution (Sigma).  Unless otherwise noted, all drugs were reconstituted in 1% 
dimethyl sulfoxide (DMSO) and used as follows: 2 µM Oligomycin, 1 µM FCCP and 1 µM 
Na2S2O (Sigma).   
2.3.2 Targeting caspase-3 in HCT116 cells 
Gene-targeting vectors were constructed by using the recombinant adeno-associated virus 
(rAAV) system as previously described [147].  Briefly, two homologous arms (1.334 kb and 
1.411 kb, respectively) flanking exons 5 and 7 of caspase-3, along with a neomycin-resistant 
gene cassette (Neo), were inserted between two Not I sites in the AAV shuttle vector pAAV-
MCS (Stratagene, La Jolla, CA).  Packaging of rAAV was performed by using the AAV Helper-
Free System (Stratagene) according to the manufacturer’s instructions.   
 
HCT116 cells containing two copies of WT caspase-3 were infected with the rAAV and 
selected by G418 (0.5 mg/ml, Mediatech, Manassas, VA) for 3 weeks.  Drug-resistant clones were 
pooled and screened by PCR for targeting events. Prior to targeting the second allele, the Neo 
cassette, which is flanked by Lox P sites, was excised from a heterozygous clone by infection with 
an adenovirus expressing Cre recombinase (Ad-Cre) [147].  Single clones were screened by PCR 
for Neo excision, and a positive clone was infected again with the same caspase-3-targeting 
construct.  After the second round, Neo was again excised by Ad-Cre infection, and gene-targeting 
in caspase-3 KO cells was verified by PCR and western blotting.  All primer sequences used are 
listed in Table 3.   
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2.3.3 Reverse transcriptase polymerase chain reaction (RT-PCR) 
Total RNA was isolated from cells using the RNAgents Total RNA Isolation System (Promega, 
Madison, Wisconsin, USA) according to the manufacturer’s instructions. First strand cDNA was 
synthesized using Superscript Reverse Transcriptase (Invitrogen) according to the 
manufacturer’s instructions. PCR was performed on a Thermo Scientific Hybaid MultiBlock 
MBS 0.2S Thermal Cycler using gene -specific primers. Primers used are listed in Table 3. PCR 
products were analyzed by agarose gel electrophoresis. 
2.3.4 Transfection  
Full-length human caspase-3 (Addgene # 11813) and catalytically dead human C163A caspase-
3 (Addgene# 11814) were obtained from Addgene (Cambridge, MA).  dsRED was a generous 
gift from Dr. Ben Van Houten at the University of Pittsburgh.  All plasmids were transfected 
with Lipofectamine 2000 (Invitrogen) according to the manufacturer’s instructions.  Stable 
clones were maintained in McCoy’s 5A supplemented with 0.4 mg/ml G418 (Gibco). 
 
2.3.5 Caspase-3 Knockdown  
Lentiviral particles were generated by co-transfection of 4 plasmids [Control plasmid 
(pLK01.GFP-puro) or the CASP3 specific shRNA plasmids pLK01.CASP3-sh1 through 5 
(Sigma), together with pMD2.g (VSVG), pVSV-REV, and pMDLg/pRRE] into 293-FT cells 
using FuGene 6 Transfection reagent (Table 3).  The collection and isolation of lentiviral 
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particles, and lentiviral transduction and screening of most effective CASP3 shRNA was carried 
out as described previously [148].  The CASP3-specific shRNA (shRNA2, Table 3) was used in 
HCT116 and RKO cells.  In brief, cells were plated and allowed to grow until 40% confluent.  
Cell media was replaced with a 1:1 dilution of lentivirus containing CASP3-shRNA2 and 
McCoy’s 5A media supplemented with 8µg/ml polybrene (Millipore).  Cells were then incubated 
at 32°C/5% CO2 for 16 hours.  Cell media was removed and replaced with fresh McCoy’s 5A, 
and cells were incubated for 8 hours at 37°C/5% CO2.  This process was repeated a second time 
before putting the cells permanently at 37°C/5% CO2 under puromycin (2 µg/ml) selection, and 
single clones were isolated by limiting dilution.  Knockdown of CASP3 was determined by 
quantitative RT-PCR using an Applied Biosystems StepOnePlus system using the Applied 
Biosystems Taqman® Gene Expression Cells-to-CT kit [148] and validated by western blotting. 
 
2.3.6 Mitochondrial fractionation 
Cytoplasmic and mitochondrial fractions were separated by Mitochondrial Fractionation Kit 
(Active Motif, Carlsbad, CA, USA) according to the manufacturer’s instructions. 
2.3.7 Cell counts 
1.5*10
6
 cells per well in a 12-well tissue culture plate were plated.  Following plating, cells were 
harvested at 24, 48, and 72 hours.  At each time point, triplicate wells for each cell type were 
spun down and reconstituted in HBSS.  Cell suspensions were then diluted 1:10 in Trypan blue 
(Gibco) and counted by hemacytometer. 
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2.3.8 Colony formation assay 
200, 400, and 600 cells of each cell type were plated in 6-well tissue culture plates.  Cells were 
maintained at 37ºC/5% CO2 and allowed to grow for 14 days with media changed every other 
day.  At the conclusion of 14 days, cell media was removed and cells were washed once with 
HBSS before staining with Crystal Violet dye for 10 minutes.  Cells were then washed 3 times 
with HBSS.  All conditions were performed in triplicate. 
2.3.9 Viability assay 
8.0 * 10
3
 cells per well were initially plated in 96-well format. Cell viability was assayed using 
Cell-Titer 96 Aqueous One Solution Cell Proliferation Assay and Cell-Titer-GLO Luminescent 
Viability Assay (Promega) according to manufacturer’s recommendations.  Long term viability 
of cells was measured by plating cells the same as above but allowing them to grow for 7, 14, or 
21 days before being assayed by CyQuant® (Life Technologies) according to manufacturer’s 
suggestions.   
2.3.10 Detection of reactive oxygen species  
Cells were plated at 20-30% confluence.  48 hours after plating, cell media was removed and 
replaced with fresh media containing 2 µM mitoSox reagents (Life Technologies).  Cells were 
then incubated for 20 minutes at 37ºC/5% CO2.  Following incubation, cells were harvested, 
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washed once in cold phosphate-buffered saline (PBS), and then reconstituted in cold 1% BSA 
PBS.  Following excitation at 518nm, 580nm emission was measured on a C6 flow cytometer 
(Accuri Cytometers).  At minimum, 30,000 events per sample were measured and all conditions 
were performed in triplicate.   
 
2.3.11 Immunoblot 
Cells were harvested in RIPA buffer (50 mM Tris pH 7.4, 150 mM NaCl, 1% Triton-X-100, 
0.1% SDS, 1% Deoxycholate, 1 mM EDTA) supplemented with protease inhibitor cocktail 
(Roche Applied Sciences).  Cells were rotated for one hour at 4ºC and then centrifuged at 13,000 
RPM for 30 minutes.  Protein concentration was determined by the Bradford assay and 40µg per 
well were loaded in 10% bis-tris gels (Life Technologies).  Gels were run for 40minutes at 180 V 
in MOPS buffer (Life Technologies).  Protein was then transferred to PVDF membranes using a 
TransBlot SD semi-dry transfer cell (Bio-Rad).  Membranes were blocked for nonspecific 
binding with 5% non-fat milk in TBS-T for one hour at room temperature and then incubated in 
primary antibody overnight at 4ºC. Primary antibodies were used at a 1:1000 dilution and include 
DRPI (ab56788), MFN2 (ab56889) (Abcam), OPA-1 (612606) (BD Transduction Laboratories), 
α-Tubulin (CP06) (Oncogene Science), β-Actin (A5441) (Sigma), and Caspase-3 (AAP103E) 
(Stressgen).  Following primary incubation, membranes were washed with TBS-T and incubated 
in appropriate HRP-conjugated secondary antibody for 1 hour at room temperature.  Secondary 
antibodies used include goat-anti-rabbit (31462), goat-anti-mouse (31432), and mouse-anti-goat 
(31400) (Pierce).  Presence of antibody binding was detected using Western Lighting - Plus ECL 
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(Perkin Elmer) according to manufacturer’s specifications.  Membranes were then exposed on 
blue X-ray film (Phenix Research Products)[149]. 
 
2.3.12 Transmission electron microscopy 
Cells grown on tissue culture plasticware were fixed in 2.5% glutaraldehyde in 100 mM PBS (8 
gm/l NaCl, 0.2 gm/l KCl, 1.15 gm/l Na2HPO4
.
7H2O, 0.2 gm/l KH2PO4,pH 7.4) overnight at 4
o
C. 
Monolayers were then washed in PBS three times then post-fixed in aqueous 1% osmium 
tetroxide, 1% Fe6CN3 for 1 hour. Cells were washed 3 times in PBS then dehydrated through a 
30-100% ethanol series then several changes of Polybed 812 embedding resin (Polysciences, 
Warrington, PA). Cultures were embedded by inverting Polybed 812-filled BEEM capsules on 
top of the cells.  Blocks were cured overnight at 37
o
C, and then cured for two days at 65
o
C. 
Monolayers were pulled off the coverslips and re-embedded for cross section. Ultrathin cross 
sections (60 nm) of the cells were obtained on a Riechart Ultracut E microtome, post-stained in 
4% uranyl acetate for 10 min and 1% lead citrate for 7 min. Sections were viewed on a JEOL 
JEM 1011 transmission electron microscope (JEOL, Peobody, MA) at 80 KV. Images were 




2.3.13 Mitochondrial outer membrane potential 
1.5*10
6
 cells per well in a 12-well tissue culture plate were plated.  48 hours following plating, 
cells were harvested, centrifuged and washed once with HBSS.  Cells were then resuspended in 
400 µl full media with 100 nM MitoTracker Red CMXRos (Molecular Probe) and incubated at 
37º C for 30 minutes.  Cells were then analyzed for positive staining by flow cytometry.  
2.3.14 Mouse xenograft studies 
All animal experiments were approved by the University of Pittsburgh Institutional Animal Care 
and Use Committee. Female 5-6 week-old Nu/Nu mice (Charles River, Wilmington, MA) were 
housed in a sterile environment with micro- isolator cages and allowed access to water and chow 
ad libitum. Mice were injected subcutaneously in both flanks with 4×10
6 
WT or caspase-3-KO 
HCT116 cells.  After implantation, tumors were allowed to grow 21 days before being sacrificed.   
2.3.15 Tissue preparation in mice 
Following treatment and sacrifice of mice, tumors were dissected and fixed in 10% formalin for 
histological analysis.  Five-micron (5µm) sections were used for tissue staining.  Histological 
analysis was performed by hematoxylin and eosin (H&E) staining.   
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2.3.16 Statistical analysis 
Statistical analyses were carried out using GraphPad Prism IV software. P values were calculated 
by the student’s t-test and were considered significant if p <0.05. The means ± standard error 
(s.e.m.) is displayed in the figures. 
2.4 RESULTS 
2.4.1 Loss of caspase-3 leads to reduced cell survival and proliferation 
In an effort to determine the role of caspase-3 in cell survival and growth we generated caspase-
3- null HCT116 colon cancer cells (C3KO) (Figure 5A).  To our surprise, we saw reduced cell 
growth of multiple C3KO clones 72 hours after seeding when counted with a hemocytometer 
following Trypan blue staining.(Figure 5B).  Reduced long term viability was further confirmed 
by CyQuant proliferation assay at 7 and 14 days after seeding (Figure 5C).  In line with reduced 
cell adhesion C3KO cells showed significantly less colony formation 14 days after seeding 
(Figure 5D).  Taken together these results show reduced cell proliferation and ability to form 
































































































WT C3KO1 C3KO2 C3KO3  
Figure 5: Caspase-3 knockout cells grow slower and form fewer colonies. 
(A)  Protein expression of HCT116 WT and C3KO cells.  (B)  WT and C3KO cell number at the 
indicated times.  (C)  WT and C3KO cell viability as measured by the CyQuant proliferation assay.  (D)  WT 
and C3KO colony formation mean values and representative images.   
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2.4.2 Caspase-3 catalytic activity is required to restore proliferation 
Following identification that loss of caspase-3 leads to a reduction in cell proliferation, C3KO 
cells were transfected with either a full length capase-3 (FLC3) expression construct, or a 
mutated catalytically dead (C163A) construct, and stable clones were generated (Figure 6A).  In 
FLC3 cells, there was a significant increase in colony formation when compared to C3KO cells 
(Figure 6B).  This increased growth was not recapitulated in C163A cells, indicating that the 
catalytic activity of caspase-3 is required for cell proliferation.   
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Figure 6: Caspase-3 catalytic activity is required to restore growth. 
(A)Protein expression in HCT116 C3KO cells expressing a full length caspase-3 expression construct 
(FLC3), or a mutated catalytically- dead caspase-3 (C163A).  (B)  Colony formation in WT, C3KO, FLC3, 
and C163A cells 14 days after seeding.   
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2.4.3 Caspase-3 knockout cells are smaller in size and have enlarged, morphologically- 
different mitochondria 
In order to determine the effect of caspase-3 loss on cell morphology, we utilized transmission 
electron microscopy.  Interestingly, while C3KO cells were significantly smaller than WT cells 
(Figure 7A-B), they contained mitochondria that were more than twice as large as WT cells 
(Figure 7A, C).  In order to confirm the altered mitochondrial morphology, WT and C3KO cells 
were transiently transfected with a dsRED expression construct that localizes to the mitochondria 
by virtue of being fused to the mitochondrial localization signal for subunit VIII of cytochrome c 
oxidase [151].  Confocal imaging of WT and C3KO cells showed less-defined mitochondria 
puncta in C3KO cells (Figure 7D).  Further analysis using Image J [152] confirmed that 
mitochondria of C3KO cells have larger mean area, perimeter, and elongation among other 
characteristics (Figure 7E and 8).     
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Figure 7: Caspase-3 knockout cells are smaller and have larger mitochondria. 
(A)  Transmission electron microscopy images of WT and C3KO cells at 3,000x and 25,000x 
magnification.  (B)  WT and C3KO mean cell size as measured from TEM images.  (C)  WT and C3KO mean 
mitochondria size as measured from TEM images.  (D)  Representative images of dsRED- transfected WT 
and C3KO cells.  (E)  Mean mitochondrial parameters shown in dsRED images as measured by Image J. 
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Figure 8: Caspase-3 knockout cells have altered mitochondrial morphology. 
(A)  Representative images of WT and C3KO mitochondria following transfection with dsRED.   
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2.4.4 Caspase-3 knockout cells have altered bioenergetics 
Following identification of altered mitochondrial morphology, we aimed to identify the 
metabolic consequence of such alteration.  Utilizing an Oroboros O2K respirometer to measure 
cellular oxidative phosphorylation capabilities, we discovered that C3KO cells consumed oxygen 
at a slower pace, indicating reduced metabolic activity (Figure 9A-B).  Furthermore, C3KO cells 
showed reduced oxygen flow per cell (Figure 9C).   
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Figure 9: Caspase-3 knockout cells have altered bioenergetics. 
(A)  Oxygen consumption and flow of WT and C3KO cells as measured by an Oroboros machine.  O 
= Oligomycin (2µM), F = FCCP (1µM).  (B)  Quantification of Oroboros chamber oxygen concentration for 
WT and C3KO cells treated as in A.  (C)  Quantification of WT and C3KO oxygen flow per cell treated as in 
A.   
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2.4.5 Caspase-3 knockout cells have increased ROS and autophagy and reduced MFN-2 
levels 
In order to determine the consequences of altered mitochondrial morphology and impaired 
cellular respiration, we examined the release of reactive oxygen species (ROS) in addition to 
basal autophagy levels, two indicators of overall mitochondrial health.  Measurement of basal 
ROS levels showed a more than two-fold increase in C3KO cells (Figure 10A).  To assess 
autophagy levels, WT and C3KO cells were transiently transfected with a GFP tagged LC3 
expression construct.  LC3II-GFP puncta were twice as prevalent in C3KO cells as in WT 
(Figure 10B).  Probing for known mitochondrial -associated proteins uncovered a drastic 
reduction in the mitochondria fusion protein MFN-2, suggesting that C3KO cells are deficient in 
mitochondrial fusion and fission (Figure 10C).  Treatment of C3KO cells with the proteasome 
inhibitor MG132 was able to rescue MFN-2 degradation (Figure 10D).   
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Figure 10: Caspase-3 knockout cells have increased ROS and autophagy and reduced MFN-2. 
(A)  Relative mitochondrial reactive oxygen species in WT and C3KO cells.  (B)  LC3II -GFP positive puncta 
in untreated WT and C3KO cells.  (C)  Protein expression in WT and C3KO cells.  Fusion = proteins involved 
in mitochondrial fusion.  Fission = proteins involved in mitochondrial fission.  (D)  Protein expression in WT 
and C3KO cells treated with MG132 (1µM) for the indicated times.   
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2.4.6 Caspase-3 knockout cells are more sensitive to glucose and glutamine deprivation 
After identifying C3KO cells as having reduced levels of oxidative phosphorylation, we aimed to 
determine if they showed a higher reliance on glucose for survival.  Reduction of glucose levels 
from 25 mM (what is normally provided in commercially-available media) to 5.5 mM resulted in 
high rates of cell death in C3KO when compared to parental lines as measured by adherent cells 
(Figure 11).  Surprisingly, C3KO cells also showed increased sensitivity to removal of the non-
essential amino acid glutamine.  Glutamine is commonly found in cell culture media at a 
concentration of 4 mM.    Combination experiments manipulating both glucose and glutamine 
showed loss of glutamine to be the more critical of the two for C3KO cell survival (Figure 11).  
These data confirm that caspase-3 knockout cells are more reliant upon glucose and glutamine to 




Figure 11: Caspase-3 knockout cells have impaired glucose/glutamine utilization. 
(A)  WT and C3KO cells maintained in varying levels of glucose +/- glutamine 5 days after seeding.  
Low = 5.5mM; High = 25mM.  Glutamine used at 4mM.  (B)  Representative phase contrast images of WT 
and C3KO cells 3 days after seeding in high glucose + glutamine media.   
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2.4.7 Caspase-3 knockdown cells recapitulate growth and mitochondrial phenotypes 
To ensure that the phenomenon we were witnessing was not an abnormality unique to HCT116 
cells or an artifact of the knockout process we generated a short hairpin construct targeting 
caspase-3 for use in other cell lines.  After expression of the construct and generation of stable 
clones, both HCT116 and RKO shCaspase-3 (shC3) cells were assayed for cell growth and 
mitochondrial morphology.  Both HCT116 shC3 and RKO shC3 showed impaired cell 
proliferation as measured by cell number, CyQuant proliferation assay, and colony formation 
assay (Figure 12).  Furthermore, RKO shC3 cells showed altered mitochondrial morphology 
similar to what was observed in HCT116 C3KO cells when compared to a GFP-expressing 
control line (Figure 13).   These results confirm that altered proliferation and mitochondrial 
morphology as a consequence of caspase-3 loss is not unique to HCT116 cancer cells.    
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Figure 12: Caspase-3 knockdown cells recapitulate reduced proliferation phenotype. 
(A)  Protein expression in RKO cells expressing either a GFP control construct (GFP) or a short 
hairpin construct targeting caspase-3 (shC3).  (B)  RKO GFP and shC3 relative cell number 96hours after 
seeding.  (C)  RKO GFP and shC3 cell viability as measured by CyQuant proliferation assay.  (D)  Protein 
expression in HCT116 cells expressing either a GFP control construct (GFP) or a short hairpin construct 
targeting caspase-3 (shC3).  (E)  Colony formation in HCT116 GFP and shC3 cells.   
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Figure 13: Caspase-3 knockdown cells recapitulate mitochondrial morphology differences. 
(A)  Representative images of RKO GFP and shC3 cells transfected with dsRED.  (B)  Mitochondrial 
reactive oxygen species in RKO GFP and shC3 cells.   
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2.4.8 Caspase-3 knockout cells show reduced viability in vivo 
In an effort to determine if the reduced proliferation of C3KO witnessed in vitro had 
physiological relevance, we injected both WT HCT116 and C3KO cells into 7 week -old nude 
mice.  C3KO cells showed a markedly reduced proliferation with tumor volumes less than half 
the size of WT (Figures 14A-B, and 15).  Additionally, C3KO tumors showed less positive 
staining for the proliferation marker PCNA (Figure 14C-D).  These data confirm that C3KO cells 
show reduced proliferation in vivo.   
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Figure 14: Caspase-3 knockout cells show reduced proliferation in vivo. 
(A)  Representative images of WT and C3KO1 xenograft tumors 21 days after injection.  (B)  
Relative average tumor volume (mm
3
).  (C)  PCNA -stained WT and C3KO tumor sections.  (D)  Relative 
PCNA -positive cells in WT and C3KO tumors.   
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Figure 15: Caspase-3 knockout tumors are smaller than WT counterparts. 




In an effort to determine the role of caspase-3 in colorectal cancer cell maintenance and death we 
generated HCT116 C3KO cells.  Much to our surprise, C3KO cells showed reduced survival and 
proliferation in the absence of treatment.  Further analysis revealed altered mitochondrial 
morphology and decreased levels of oxidative phosphorylation.  Preliminary data suggests that a 
reduction in the mitochondrial fusion protein MFN-2 may have a role in altering mitochondrial 
function, but further investigation is needed.   
Historically, there has been a plethora of knowledge on the role of caspases in cell death, 
yet little is known about the role of caspases in metabolism.  However, knowledge of caspase 
involvement in metabolic processes has emerged in recent years.  Caspase-1-dependent 
production of the inflammatory cytokines IL-1 and IL-18 has been shown to be critical in the 
regulation of appetite, body weight, glucose homeostasis, and lipid metabolism [153].  Recent 
work suggests that caspase-3 might also have metabolic roles.  In response to resveratrol 
treatment, cancer cells show a shift in hemoglobin conformation from the T to R state which 
results in the alteration of the cell’s metabolic balance and an overall shift to intensification of 
the pentose phosphate pathway.  This leads to higher oxygen levels and activation of caspase-3.  
Caspase-3, in turn, cleaves Band 3 which inhibits anion transport resulting in lower ROS levels 
[154, 155].  These results lend support to the reduced ROS levels seen in our experiments when 
caspase-3 was present.   
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The outer mitochondrial membrane GTPase mitofusin 2 (MFN2) was reduced in C3KO 
cells and might be responsible for the altered mitochondrial morphology and reduced cell 
survival.  In MFN2 -null mouse embryonic fibroblasts, investigators found an increase in ER 
chaperone proteins, ER stress, and exacerbated ER stress-induced apoptosis [156].  MFN2 
knockout cell models also show swollen mitochondria and a reduction in spare respiratory 
capacity, both of which are mimicked in our cells [157].  The amount of overlap between MFN2 
knockout models and our system coupled with the reduced levels of MFN2 in C3KO cells 
suggests that caspase-3 might be regulating MFN2 levels.  The E3-ubiquitin ligase Parkin is the 
best known regulator of MFN2.  In response to mitochondrial depolarization PTEN induced 
putative kinase 1 (PINK1) is activated and translocates to the mitochondria where it 
phosphorylates and activates Parkin.  Parkin then ubiquitinates MFN2 targeting it for 
proteosomal degradation [158, 159].  Perhaps caspase-3 is responsible for cleaving PINK1 or 
another kinase with similar function.  If this were the case, restoration of caspase-3 would lead to 
reduced ubiquitination and degradation of MFN2.  This hypothesis is also in line with the 
necessity of caspase-3 being catalytically active.  Reconstitution of C3KO cells with C163A 
catalytically dead caspase-3 showed no improvement in cell growth when compared to C3KO 
cells expressing a GFP control (Figure 6).  While our data suggest a possible connection between 
caspase-3 and MFN2 (Figure 16) further investigation will need to be conducted to determine if 
loss of MFN2 is the cause behind our phenotype or merely a consequence of it.   
C3KO xenografts had reduced tumor volume and proliferation when compared to WT 
counterparts lending credence to the validity of our findings in vivo.  Having determined this, it 
is worthwhile to further investigate targeted therapies inhibiting caspase-3 activity in CRC 
patients as they may prove beneficial in slowing and or reducing tumor volumes to a point where 
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surgical removal can more easily be performed.  Caspase-3 is widely known for its role as an 
executioner caspase in the apoptotic response but little more.  We have identified caspase-3 as a 
key protein in the regulation of mitochondrial morphology and cellular metabolism and 
proliferation.  These results may prove beneficial in advancing therapies focused on exacerbating 




Figure 16: A model for the potential interaction between caspase-3 and MFN2 
Multiple phenotypes found in C3KO cells are consistent with what is found in MFN2 knockout 
models.  It is our hypothesis that caspase-3 may play a role in regulation of MFN2 degradation.    
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3.0  CASPASE-3 SUPPRESSES DNA DAMAGE-INDUCED AND RIP1-DEPENDENT 
NECROSIS 
3.1 ABSTRACT  
Caspase-3 is a cysteine protease best known to execute apoptosis.  We generated caspase-3 null 
(C3KO) HCT 116 human colorectal cancer cells and found they were sensitized to DNA 
damaging agents including 5-FU, Etoposide and Camptothecin, but not to TNF-  Compared to 
parental cells, C3KO cells had intact apoptosis and underwent RIP1- and ROS-dependent, but 
RIP3-independent, necrosis.  Drug-induced necrosis was blocked by the expression of full length 
or catalytically deficient caspase 3 in C3KO cells.  Knockdown of Caspase 3 in HCT 116 and 
RKO cells also enhanced sensitivity and necrosis to DNA damaging agents.  5-FU treatment led 
to recruitment of the unprocessed caspase 3 to a complex containing caspase-8, FADD and RIP1 
in HCT 116 cells.  Genetic ablation of caspase-3 or pan caspase inhibitor z-VAD stabilized a 
necrotic complex containing caspase-8, RIP1 and FADD.  DR5, caspase-8, and FADD were 
found to be required for 5-FU-induced apoptosis and necrosis in C3KO cells.  Furthermore, 
C3KO tumors exhibited enhanced response and necrosis to 5-FU in vivo.  These data 
demonstrate a novel function of caspase-3 in suppressing RIP1- and caspase-8-dependent 
necrosis induced by genotoxic stress, which might be exploited in cancer therapy. 
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3.2 BACKGROUND 
Colorectal cancer is the fourth most common form of cancer in the United States and is 
responsible for the second largest number of cancer associated deaths [3].  Chemotherapy is a 
common treatment for patients with Stage III or stage IV colon cancer, and the combination of 
DNA damaging agents such as 5-Fluorouracil (5-FU) and irinotecan (Camptosar) is often used 
[3].  The 5-yr survival of patients with Stage IV or more advanced disease is only 6% even with 
these aggressive treatments, and new therapies are urgently needed [3].  During transformation, 
neoplastic cells become resistant to apoptosis as a result of genetic and epigenetic alterations, 
driving accumulation of additional oncogenic events, and resistance to chemotherapy and 
radiation [15, 160, 161].  The exploration of alternative death pathways might provide new 
therapeutic options.   
Apoptosis is initiated by two major pathways in mammalian cells.  Engaging the 
mitochondria-dependent intrinsic and death receptor-dependent extrinsic apoptotic pathways leads 
to the activation of initiator caspases-9 and -8, respectively, which in turn activate executioner 
caspases-3 and -7 [160, 161].  Caspase-3-dependent apoptosis in both cancer cells and the stroma 
was found to stimulate growth of cancer cells following radiation therapy for tumor repopulation, 
and higher levels of activated caspase-3 is associated with increased recurrence and shorter 
survival [162].  Additionally, caspase-3 is found to play nonapoptotic roles such as regulation of 
brain development and stem cell differentiation [82, 84, 86].  All of these functions are dependent 
upon its enzymatic activity, while little is known about non-enzymatic functions of caspase-3.   
Necrosis has long been viewed as an unregulated form of cell demise that promotes 
inflammation and tissue damage.  However, emerging evidence indicates that some forms of 
necrosis are programmed, and proceed through an orderly process that is initiated at the cell 
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surface upon activation of the extended TNF- receptor family, and propagates through the 
receptor-interacting serine threonine kinases, RIP1 and RIP3 [163-166].  Blocking apoptosis 
genetically by caspase 8 ablation or using pan-caspase inhibitor z-VAD is often required to induce 
programmed necrosis in a context- and cell type-dependent manner.  In mice, caspase-8 suppresses 
RIP3-dependent necrosis during development [167, 168], and intestinal necrosis associated with 
inflammation involving the production of TNF- [154, 155].  In cancer cells, TNF- -induced 
necrosis has recently been investigated at the molecular level, and MLKL and PGAM5 were found 
to mediate events downstream of RIP1/RIP3 through the mitochondria [96, 97].  In most of these 
studies, necrosis is induced by a combination of TNFα, the pan caspase inhibitor z-VAD, and 
sometimes further enhanced by SMAC mimetics that deplete both ring-containing E3 ubiquitin 
ligases cIAP1 and cIAP2.  Limited evidence suggests that necrotic cell death can occur 
independent of either RIP1, RIP3 [169, 170] or both [171].  In contrast, little is known about DNA 
damage-induced necrosis despite its potential significance in cancer therapy.   
In the current study, we report a novel function of caspase-3, independent of its enzymatic 
function, in suppressing necrosis triggered by genotoxic stress in colon cancer cells.  In an attempt 
to establish an apoptosis-resistant cancer cell model, we generated caspase-3 null (C3KO) 
HCT116 colon cancer cells.  Unexpectedly, caspase-3 KO cells showed normal apoptotic 
response, but were significantly more sensitive to DNA damaging agents, but not to TNFα, 
compared to their wild-type counterparts.  Elevated cell death induced by 5-FU and other DNA 
damaging agents in these cells was attributable to RIP1 and reactive oxygen species (ROS)-
dependent necrosis, and a complex containing caspase-8/RIP1/FADD.  This form of necrosis is 
RIP3-independent and requires death receptor DR5, caspase 8, and the adaptor protein FADD.   
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3.3 MATERIALS AND METHODS 
 
3.3.1 Cell culture and drug treatment 
Human colorectal cancer cell lines, including HCT116, HT29 and RKO and embryonic kidney 
293T cells were obtained from the American Type Culture Collection (Manassas, VA, USA). 
RKO, HT29, HCT116 and derivative cell lines were cultured in McCoy’s 5A modified media 
(Life Technologies) at 37ºC/5% CO2.  293T cells were maintained in DMEM (Life 
Technologies) media at 37ºC/5% CO2.  All media was supplemented with 10% FBS and 1% 
Penicillin-Streptomycin solution (Sigma).  Unless otherwise noted all drugs were reconstituted in 
1% dimethyl sulfoxide (DMSO) and used as follows: 50 µg/ml 5-fluorouracil (5-FU), 100 µM 
Etoposide (Etop), 750 nM Camptothecin (CPT), 15 µM Necrostatin-1 (Nec-1) (Sigma) and 20 
µM Z-VAD-FMK (z-VAD) (BaChem). 
3.3.2 Targeting Caspase-3 in HCT116 cells 
Gene targeting vectors were constructed by using the recombinant adeno-associated virus 
(rAAV) system as previously described [147].  Briefly, two homologous arms (1.334 kb and 
1.411 kb, respectively) flanking exons 5 and 7 of caspase-3, along with a neomycin-resistant 
gene cassette (Neo), were inserted between two Not I sites in the AAV shuttle vector pAAV-
MCS (Stratagene, La Jolla, CA).  Packaging of rAAV was performed by using the AAV Helper-
Free System (Stratagene) according to the manufacturer’s instructions.   
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HCT116 cells containing two copies of WT Casapse-3 were infected with the rAAV and 
selected by G418 (0.5 mg/ml, Mediatech, Manassas, VA) for 3 weeks.  Drug-resistant clones were 
pooled and screened by PCR for targeting events. Prior to targeting the second allele, the Neo 
cassette, which is flanked by Lox P sites, was excised from several heterozygous clones by 
infection with an adenovirus expressing Cre recombinase (Ad-Cre) [147].  Single clones were 
screened by PCR for Neo excision, and positive clone for independent heterozygotes was infected 
again with the same caspase-3-targeting construct.  After the second round, Neo was again excised 
by Ad-Cre infection, and gene targeting in caspase-3 KO cells was verified by PCR and western 
blotting.  All primer sequences used are listed in Table 3.  FADD KO HCT116 cells were 
generated in Yu lab using a similar approach [153]. 
 
3.3.3 Reverse transcriptase polymerase chain reaction (RT-PCR) 
Total RNA was isolated from cells using the RNAgents Total RNA Isolation System (Promega, 
Madison, Wisconsin, USA) according to the manufacturer’s instructions. First strand cDNA was 
synthesized using Superscript Reverse Transcriptase (Invitrogen) according to the 
manufacturer’s instructions. PCR was performed on a Thermo Scientific Hybaid MultiBlock 
MBS 0.2S Thermal Cycler using gene specific primers. Primers used are listed in Table 3. PCR 





Table 3: Sequences used in experiments 
Target   Sequence 
Caspase-3 Right Arm Forward 1 5’-CTGGGAAGATAGCAGGGTTTGTGT-3' 
  Right Arm Reverse 1 5’-TTTGTGAGCATGGAAACAATACATGT-3' 
  Left Arm Forward 1 5’-AGAACTGGACTGTGGCATTGAG-3’ 
  Left Arm Reverse 1 5'-GCTTGTCGGCATACTGTTTCAG-3’ 
Neomycin Forward 1 5’-TCTTGACGAGTTCTTCTGAG-3’ 
  Reverse 1 5’-TTGTGCCCAGTCATAGCCG-3' 
GAPDH Forward 1 5’-TGCACCACCAACTGCTTAGC-3’ 
  Reverse 1 5’-GGCATGGACTGTGGTCATGAG-3’ 
RIP1 Forward 1 5’-GGCGTCATCATAGAGGAAGG-3’ 
  Reverse 1 5’-TGTGTATCACGCCTTTTCCA-3’ 
RIP2 Forward 1 5’-GGAATTATCTCTGAACATACCTG-3’ 
  Reverse 1 5’-CCTGGACAGAAGGGCATCTAGC-3' 
RIP3 Forward 1 5’-TGCTGGAGGAGAAGTTGAGTTGC-3’ 
  Reverse 1 5’-CTGTTGCACACTGCTTCGTACAC-3’ 
      
Control siRNA 5'-AACGUACGCGGAAUACUUCGA-3' 
Caspase-8 siRNA 5’-AAGAGTCTGTGCCCAAATCAA-3’ 
DR5 siRNA 5'-AAGACCCUUGUGCUCGUUGUC-3' 
      
Control shRNA 5'-CCGCAGGTATGCACGCGT-3' 
RIP1 shRNA 5’-TAAGCTGAAAGAACATGACCT-3’ 
Caspase-3 shRNA1 5'-GCGAATCAATGGACTCTGGAA-3' 
  shRNA2 5'-CCTGAGATGGGTTTATGTATA-3' 
  shRNA3 5'-CCGAAAGGTGGCAACAGAATT-3' 
  shRNA4 5'-CTAAAGGTGGTGAGGCAATAA-3' 
  shRNA5 5'-GTGGAATTGATGCGTGATGTT-3' 
   
RIP3 Expression plasmid F 5’-TTCAAGCTTGATGTCGTGCGTCAAGTTATGGCC-3’ 





Expression plasmid F 5’-GATGTGGCGGTCGCAATCGTAAACTCG-3’ 
RIP3-
K50A 




3.3.4 Transfection  
Full-length human caspase-3 (Addgene # 11813) and catalytically dead human C163A caspase-3 
(Addgene# 11814) were obtained from Addgene (Cambridge, MA).  RIP1 lacking the entire 
kinase domain rendering it dominant negative was a generous gift from Dr. Junying Yuan at 
Harvard University.  All plasmids were transfected with Lipofectamine 2000 (Invitrogen) 
according to the manufacturer’s instructions.  Stable clones were maintained in McCoy’s 5A 
supplemented with 0.4 mg/ml G418 (Gibco). 
Small-interfering RNA (siRNA) duplexes were obtained from Qiagen (Venlo, 
Netherlands) and include: caspase-8, DR5 and control scrambled siRNA (Table 3).  siRNA 
duplexes were transfected with Lipofectamine 2000 according to the manufacturer’s instructions 
with minor modifications.  Briefly, 400 pmols of siRNA duplexes were transfected into cells in 
12-well plates for 4 hours, followed by incubation in medium containing 5% FBS for 20 hours, 
and then drug treatment in complete media containing 10% FBS. 
The HA-tagged full length RIP3 expression vector was constructed by cloning RT-PCR 
products into the pcDNA3.1-N-HA vector (Invitrogen).  Variants of this vector including the 
K50A point mutation rendering RIP3 catalytically dead were constructed similarly.  Sequences 
used are listed in table 3.   
 
3.3.5 Caspase-3 and RIP1 Knockdown  
Lentiviral particles were generated by co-transfection of 4 plasmids [Control plasmid 
(pLK01.GFP-puro) or the CASP3 specific shRNA plasmids pLK01.CASP3-sh1 through 5 
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(Sigma), together with pMD2.g (VSVG), pVSV-REV and pMDLg/pRRE] into 293-FT cells 
using FuGene 6 Transfection reagent (Table 3).  The collection and isolation of lentiviral 
particles, and lentiviral transduction and screening of most effective CASP3 shRNA was carried 
out as described previously [148].  The CASP3-specific shRNA (shRNA2, table 3) was used in 
HCT116, RKO and FADD KO cells.  In brief, cells were plated and allowed to grow until 40% 
confluent.  Cell media was replaced with a 1:1 dilution of lentivirus containing CASP3-shRNA2 
and McCoy’s 5A media supplemented with 8µg/ml polybrene (Millipore).  Cells were then 
incubated at 32°C/5% CO2 for 16 hours.  Cell media was removed and replaced with fresh 
McCoy’s 5A and cells were incubated for 8 hours at 37°C/5% CO2.  This process was repeated a 
second time before putting the cells permanently at 37°C/5% CO2 under puromycin (2 µg/ml) 
selection, and single clones were isolated by limiting dilution.  Knockdown of CASP3 was 
determined by quantitative RT-PCR using an Applied Biosystems StepOnePlus system using the 
Applied Biosystems Taqman® Gene Expression Cells-to-CT kit [148], and validated by western 
blotting. 
RIP1 knockdown lines were generated in a slightly different manner.  In brief, 293T cells 
were plated in 12 well format and allowed to grow to 90% confluence, and transfected with 4 
plasmids with Lipofectamine 2000 (Invitrogen), including pLK shRIP1 (Open Biosystems), 
pMD2.G (0.5 µg), pMDLg-pRRE (0.5 µg) and pRSV-Rev (0.5 µg) according to the 
manufacturer’s instructions. Sequence data is provided in Table 3.  Forty-eight hours after 
transfection, the viral supernatant was harvested with a syringe and needle.  Supernatant was then 
passed through a 0.45µm filter and mixed 4:1 with McCoy’s 5A containing 8 µg/ml polybrene.  
Virus/media mixture was then added to HCT116 caspase-3 KO cells for 48 hours.  Cells were 
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permanently maintained at 37°C/5% CO2 under puromycin (2 µg/ml) selection, and single clones 
were isolated by limiting dilution.   
 
3.3.6 Cell viability 
Cells were plated at 20-30% confluence 24 hours prior to treatment.  Unless noted otherwise, 
cells were treated for 48 hours. Cell viability was assayed using Cell-Titer 96 Aqueous One 
Solution Cell Proliferation Assay and Cell-Titer-GLO Luminescent Viability Assay (Promega) 
according to manufacturer’s recommendations.  In some experiments, treated cells were washed 
3 times with HBSS and stained with crystal violet dye (Sigma) for 10 minutes, followed by 3 
more rinses with HBSS.  All experiments were repeated for at least 3 times.   
 
3.3.7 Mitochondrial outer membrane potential 
Cells were plated at 20-30% confluence 24 hours prior to treatment.  Following treatment, cells 
were assayed for mitochondrial outer membrane potential by MitoTracker Red CMXRos 
according to manufacturer’s recommendations as previously described [172].  
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3.3.8 Propidium iodide and annexin V staining 
Cells were plated at 20-30% confluence 24 hours prior to treatment.  Following 48 hours 
treatment, cells were trypsinized and spun down at 3,000 RPM.  Cells were then washed in cold 
PBS and reconstituted in 100µl of Annexin-binding buffer (10mM HEPES, 140 mM NaCl, 2.5 
mM CaCl2, adjusted to pH=7.4) containing 2 µl of Annexin V-Alexa Fluor 488 and 2 µl 50 
µg/ml propidium iodide (Invitrogen).  Cells were then allowed to incubate in the dark at room 
temperature for 15 minutes before being diluted with 300 µl Annexin-binding buffer.  FL1 and 
FL2 emission was measured on a C6 flow cytometer (Accuri Cytometers).  At minimum, 30,000 
events per sample were measured and all experiments were performed in triplicate  
 
3.3.9 Detection of reactive oxygen species   
Cells were plated at 20-30% confluence 24 hours before treatment and then treated for 24 hours.  
Following treatment, cell media was removed and replaced with fresh media containing 2 µM 
mitoSox reagents (Life Technologies).  Cells were then incubated for 20 minutes at 37ºC/5% 
CO2.  Following incubation cells were harvested washed once in cold phosphate-buffered saline 
(PBS) and then reconstituted in cold 1% BSA PBS.  Following excitation at 518 nm, 580 nm 
emission was measured on a C6 flow cytometer (Accuri Cytometers).  At minimum, 30,000 




Cells were harvested in RIPA buffer (50 mM Tris pH 7.4, 150 mM NaCl, 1% Triton-X-100, 
0.1% SDS, 1% Deoxycholate, 1 mM EDTA) supplemented with protease inhibitor cocktail 
(Roche Applied Sciences).  Cells were rotated for one hour at 4ºC and then centrifuged at 13,000 
RPM for 30 minutes.  Protein concentration was determined by the Bradford assay and 40 µg per 
well was loaded in 10% bis-tris gels (Life Technologies).  Gels were run for 40 minutes at 180v 
in MOPS buffer (Life Technologies).  Protein was then transferred to PVDF membranes using a 
TransBlot SD semi-dry transfer cell (Biorad).  Membranes were blocked for nonspecific binding 
with 5% nonfat milk in TBS-T for one hour at room temperature and then incubated in primary 
antibody overnight at 4ºC. Primary antibodies were used at a 1:1000 dilution and include 
HMGB1 (ab18256), DR5 (ab8416) (Abcam); FADD (F36620), RIP1 (610458), Ubiquitin 
(550944) (BD Transduction Laboratories); Caspase-7 (9492), Caspase-8 (9746), Caspase-9 
(9502), p-p53 (9284) (Cell Signaling);  RIP3 (IMG-5846A) (Imgenex); γ-H2AX (07-164) 
(Millipore); α-Tubulin (CP06), Noxa (OP180), (Oncogene Science); PUMA (3795) [173], cIAP1 
(AF8181) (R&D); HA (sc-805) (Santa Cruz); Flag (F3165), β-Actin (A5441) (Sigma) and 
Caspase-3 (AAP103E) (Stressgen).  Following primary membranes were washed with TBS-T 
and incubated in appropriate HRP-conjugated secondary for 1 hour at room temperature.  
Secondary antibodies used include goat-anti-rabbit (31462), goat-anti-mouse (31432) and 
mouse-anti-goat (31400) (Pierce).  Presence of antibody binding was detected using Western 
Lighting - Plus ECL (Perkin Elmer) according to manufactures specifications.  Membranes were 
then exposed on blue X-ray film (Phenix Research Products) [149]. 
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3.3.11 Transmission electron microscopy 
Cells grown on tissue culture plasticware were fixed in 2.5% gluaraldehyde in 100 mM PBS (8 
gm/l NaCl, 0.2 gm/l KCl, 1.15 gm/l Na2HPO4
.
7H2O, 0.2 gm/l KH2PO4, pH 7.4) overnight at 4
o
C. 
Monolayers were then washed in PBS three times then post-fixed in aqueous 1% osmium 
tetroxide, 1% Fe6CN3 for 1 hr. Cells were washed 3 times in PBS then dehydrated through a 30-
100% ethanol series then several changes of Polybed 812 embedding resin (Polysciences, 
Warrington, PA). Cultures were embedded in by inverting Polybed 812-filled BEEM capsules on 
top of the cells.  Blocks were cured overnight at 37
o
C, and then cured for two days at 65
o
C. 
Monolayers were pulled off the coverslips and re-embedded for cross section. Ultrathin cross 
sections (60 nm) of the cells were obtained on a Riechart Ultracut E microtome, post-stained in 
4% uranyl acetate for 10 min and 1% lead citrate for 7 min. Sections were viewed on a JEOL 
JEM 1011 transmission electron microscope (JEOL, Peobody MA) at 80 KV.  Images were 




The protocol was modified from [174]. In brief, following harvesting of cells, 5 mg of protein 
reconstituted in 1 ml of RIPA per condition was used in conjunction with the Invitrogen Protein 
A and G Dynabead® immunoprecipitation system according to manufacturer’s 
recommendations.  Antibodies used include RIP1 (610458) (BD Transduction); Caspase-3 (sc-
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7148) and Caspase-8 (sc-6136) (Santa Cruz).  Resulting precipitates were processed in the same 
manner as other immunoblots noted above [174]. 
 
3.3.13 Xenograft studies  
All animal experiments were approved by the University of Pittsburgh Institutional Animal Care 
and Use Committee. Female 5–6 week-old Nu/Nu mice (Charles River, Wilmington, MA) were 
housed in a sterile environment with micro isolator cages and allowed access to water and chow 
ad libitum. Mice were injected subcutaneously in both flanks with 4×10
6 
WT or caspase-3-KO 
HCT116 cells.  After implantation, tumors were allowed to grow 7 days before treatment was 
initiated.  Mice were randomized into two groups (n = 9 per group) receiving either vehicle 
(PBS) or 5-FU (50 mg/kg/d) every other day for 14 days.  Detailed methods on tumor 
measurements, harvests and histological analysis are as described [175, 176]. 
 
3.3.14 Tissue preparation and analysis of histology and Immunohistochemistry (IHC)  
Following sacrifice of mice, tumors were dissected and fixed in 10% formalin for histological 
analysis as described previously [175, 176].  Five-micron (5 µm) sections were used for staining.  
Histological analysis was performed by hematoxylin and eosin (H&E) staining.  Cell death was 
analyzed by TUNEL staining with the ApopTag Fluorescein In Situ Apoptosis Detection Kit 
(Chemicon International, Temecula, CA) according to the manufacturer’s instructions. 
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Activated caspase-3 IHC was performed as described [177].  In brief, tissue sections (5µm) 
were deparafinized, rehydrated through graded ethanol and treated with 3% hydrogen peroxide. 
Antigen retrieval was performed by boiling the sections for 10 minutes in 0.1 M citrate buffer (pH 
6.0) with 1 mM EDTA. Non-specific antibody binding was blocked using 20% goat serum at room 
temperature for 30 minutes. Sections were incubated overnight at 4°C in a humidified chamber 
with 1:100 diluted rabbit-anti-caspase-3 (cleaved, Asp 175) (9661; Cell Signaling Technologies, 
Beverly, MA). Sections were then incubated for 1 h at room temperature with biotinylated goat-
anti-rabbit secondary antibodies (#31822; Pierce) and developed with an ABC kit and DAB 
(Vector Laboratories, Burlingame, CA). 
 
3.3.15 Statistical Analysis 
Statistical analyses were carried out using GraphPad Prism IV software. P values were calculated 
by the student’s t-test and were considered significant if p <0.05. The means ± standard error 
(s.e.m.) is displayed in the figures. 
3.4 RESULTS 
3.4.1 Caspase-3 knockout cells are more sensitive to DNA damaging agents 
To model apoptosis resistance, we generated several caspase-3 KO (C3KO) HCT116 human 
colon cancer cell lines using the recombinant adeno-associated virus (rAAV) mediated gene 
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targeting (Figure 17A).  This line was chosen because of its well-characterized responses to a 
wide range of anti-cancer agents and prior successes in gene targeting.  Deletion of exon 5-7 of 
Caspase-3 gene was verified by polymerase chain reaction (PCR) (Figure 17B), and complete 
loss of protein expression was confirmed by western blot (Figure 17C).  Unexpectedly, C3KO 
cells were found to be significantly more sensitive to common chemotherapeutics and DNA 
damaging agents including 5-flurouracil (5-FU), Camptothecin (CPT) and Etoposide (Etop) 




Figure 17: Caspase-3 knockout cells are more sensitive to DNA damaging agents. 
(A) Schematic representation of caspase-3 genomic locus and the targeting constructs and strategy.  
NeoF, NeoR, P1 and P2 are PCR primers (sequences in Table 3) for identifying knockout clones. (B) PCR 
analysis with primers P1 and P2 showing both full length (WT) and targeted caspase-3 allele (C3KO).  (C)  
Protein expression of caspase-3 in HCT116 WT and 3 independent C3KO clones.   (D) Formazan production 
by HCT116 WT and C3KO cells treated with Camptothecin (500 nM), Etoposide (50 µM) or 5-FU (50 µg/ml) 
for 48h.  (E)  Quantification of PI+/Annexin V+ cells for cells treated as in A.  (F) Adherent cells 48h after 5-
FU (50 µg/ml) treatment stained by crystal violet.  (G) Cellular ATP levels following 5-FU (50 µg/ml) 
treatment at the indicated times. Values were normalized to the DMSO treated cells.  (H)  Mitochondrial out 
membrane potential following 48h treatment with 5-FU (20 µg/ml).  (I)  Quantification of cells in (H) with 
decreased mitochondrial out membrane potential.  **p<.01 
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Flow cytometry analysis showed highly elevated cell death in C3KO cells evidenced by the 
propidium iodide (PI) +/Annexin V+ population (Figure 17E).  Reduction of adherent cells, 
cellular ATP levels and mitochondrial outer membrane potential further validated increased 
sensitivity of C3KO cells to 5-FU (Figure 17F-I).  However, the fraction of Annexin V+, or 
apoptotic cells was nearly identical in WT and C3KO cells (Figure 18A).  This is consistent with 
largely intact activation of caspase-7, -9, but not caspase-8, C3KO cells (Figure 18B).  Markers of 
DNA damage response were also indistinguishable in WT and C3KO cells, including γ-H2AX, 
phosphorylated p53 (S15), induction of p53 targets PUMA, Noxa and p21, and depletion of cIAP1 
(Figure 18C).  These findings demonstrate that caspase-3 is dispensable for DNA-damage induced 
apoptosis, but suppresses non-apoptotic cell death. 
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Figure 18: Apoptosis is not compromised in caspase-3 KO cells. 
HCT 116 and C3KO cells were treated with 5-FU (50 µg/ml).  (A) Fractions of Annexin V+ cells 48 h 
after treatment.  (B) Western blots of the indicated caspases 24h after 5-FU treatment.  The full length 
proteins were underlined. (C)  Western blots of the indicated DNA damage response associated proteins 24h 
after 5-FU treatment. 
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3.4.2 DNA damage induces necrosis in caspase-3 KO cells  
Significantly increased PI+ populations in C3KO cells suggested activation of non-apoptotic cell 
death after 5-FU treatment (Figure 19A).  The release of nuclear protein HMGB1 into the culture 
media is a marker for necrosis [178], and was readily detected in 5-FU treated C3KO cells, but 
not in WT cells (Figure 19B).  The pan caspase inhibitor z-VAD-FMK (z-VAD) had no affect on 
the PI+/Annexin V- populations, while significantly reduced the Annexin V+ apoptotic 
populations in both WT and C3KO cells (Figure 19C).  Transmission electron microscopy 
revealed classical morphologic signs of necrosis in C3KO cells, such as complete leakage of 
nuclear content and membrane disintegration (Figure 19D).  Characteristic signs of apoptosis 
such as condensed and fragmented nuclei were found in both WT and C3KO cells (Figure 19D).  
Stable expression of the full length caspase-3 (FLC3) or a catalytically dead mutant (C163A) 
[179] in C3KO cells specifically reduced PI+/Annexin V- cells and HMGB1 release to the levels 
found in WT cells (Figures 19E-G and 20B-D).  C3KO cells also showed a significant increase 
in PI+/Annexin V- populations and HMGB1 release after CPT or Etoposide treatment (Figure 
19H-I).  These findings demonstrate that caspase-3 suppresses DNA damage-induced necrosis 
independent of its enzymatic activity. 
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Figure 19: Induction of necrosis in 5-FU treated caspase-3 KO cells. 
(A)  Fractions of PI+ (dying) cells in HCT116 WT and C3KO cells treated with 5-FU (50 µg/ml) for 
48h.  (B) The levels of HMGB1 released into culture medium and RIP1 48h post 5-FU (50 µg/ml) treatment.  
(C) Fractions of PI+/Annexin V- (top) or Annexin V+ (bottom) cells 48h after 5-FU (50µg/ml) treatment with 
or without z-VAD (20 µM).  (D) Representative images of transmission electron microscopy of cells 24h after 
5-FU (50 µg/ml) treatment.  White arrows denote apoptotic cells, black arrows denote necrotic cells.  (E) 
Reconstitution of either full length caspase-3 (FLC3) or catalytically dead mutant (C163A) in C3KO cells 
confirmed by western blotting.  (F)  Fractions of PI+/Annexin V- in C3KO cells reconstituted with either full 
length caspase-3 or catalytically dead C163A mutant 48r after 5-FU (50 µg/ml) treatment.  (G) The levels of 
HMGB1 in the medium of reconstituted C3KO cells 48h after 5-FU (50 µg/ml) treatment.  **p<.01.  (H)  
Fractions of PI+/annexin V- cells in WT and C3KO HCT116 cells 48h after CPT (500 nM) or Etoposide (50 
µM) treatment.   (I)  The levels of HMGB1 in the medium of cells treated as in (H).  
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Figure 20: Induction of necrosis by DNA damage in caspase-3 KO cells. 
HCT 116 and C3KO cells were treated with 5-FU (50 µg/ml) and stained by PI and annexin V, or 
mitoSox for cell death or ROS analyses.  (A) Flow cytometry profiles of cells stained with PI and annexin V 
48h after 5-FU treatment with or without z-VAD (20 µM).  (B)  Flow cytometry profiles for C3KO cells 
reconstituted with FLC3 or C163A mutant stained with PI and annexin V 48h after 5-FU treatment.  (C)  
Caspase-3 activation in FLC3 and C163A reconstituted C3KO1 cells 24h after 5-FU (50 µg/ml) treatment was 




3.4.3 Necrosis in caspase-3 KO cells is RIP1-and ROS-dependent but RIP3-independent 
We then investigated potential roles of receptor-interacting serine/threonine-protein kinase 
(RIPs) in 5-FU-induced necrosis.  The expression of RIP 1 and RIP2 but not RIP3 mRNA was 
detected by RT-PCR analysis in HCT 116 or C3KO cells (Figure 21A).  RIP1, but not RIP3, 
protein was detected in HCT 116 and C3KO cells (Figures 19B and 21B).  Exogenous 
expression of WT RIP3 or a kinase dead mutant (RIP3, K50A) did not increase necrosis in either 
WT or C3KO cells (Figures 21C-E).  A highly potent, specific small molecule inhibitor of RIP1, 
Necrostatin-1 (Nec-1), or expression of either a short-hairpin RNA (shRNA) against RIP1 or 
kinase domain deleted (DN) RIP1 significantly reduced the PI+/Annexin V- population and 
HMGB1 release in 5-FU treated C3KO cells (Figures 22A-C).  RIP1 KD, or RIP1 DN did not 
significantly reduce caspase-7 or-9 activation or apoptosis in C3KO cells (Figure 22C).  Co-
treatment of cyclohexamide and TNFα led to increased apoptosis but not necrosis in both WT 
and C3KO cells (Figure 23), consistent with a requirement of RIP3 for TNFα-induced necrosis. 
Necrosis can occur in both a reactive oxygen species (ROS) -dependent and independent 
manner [97].  A significant increase in ROS production was detected in C3KO cells over WT cells 
24 hours after 5-FU treatment (Figure 22D).  Treatment with ROS scavenger glutathione (GSH) 
reduced 5-FU induced necrosis as measured by PI+/Annexin V- cells and HMGB1 release (Figures 
22E-F and 24A), while RIP1 knockdown did not affect ROS production in either WT or C3KO 
cells (Figure 24B).  These data strongly suggest that increased sensitivity to 5-FU in C3KO cells is 
driven by RIP1- and ROS-dependent necrosis, and ROS likely acts upstream of RIP1. 
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Figure 21: Caspase-3 KO cells die by RIP3-independent necrosis. 
(A) RIP1, 2 and 3 levels were analyzed by RT-PCR in the indicated cells before or after 48h 5-FU 
(50µg/ml) treatment.  (B)  RIP3 protein levels analyzed by western blotting in the indicated colon cancer cells.  
(C) Expression of the full length RIP3 or catalytically dead mutant (K50A) analyzed in HCT116 WT or 
C3KO cells after transient transfection. (D)  The levels of HMGB1 in the medium of cells transfected 
expression FL or K50A RIP3 48h after 5-FU (50 µg/ml) treatment.  (E)   Fractions of PI+/Annexin V- cells 
treated as in (D).  **p<.01 
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Figure 22: Caspase-3 KO cells die by RIP1 and ROS dependent necrosis. 
(A)  Stable expression of shRIP1 or dominant negative RIP1 (RIP1-DN) in HCT116 C3KO cells was 
confirmed by western blotting.   (B)  Fractions of PI+/Annexin- cells 48h after 5-FU (50 µg/ml) treatment with 
or without necrostatin-1 (15 µM).  (C) The levels of HMGB1release (medium) and caspase-7 and-9 from 
indicated cells 48h after 5-FU (50 µg/ml) treatment.  (D) Production of reactive oxygen species measured by 
mitoSox (Mt. ROS) in the indicated cells 24h after 5-FU (50 µg/ml) treatment with or without GSH (10 µM) 
treatment.  (E) Fractions of PI+/Annexin V- C3KO cells at 48h after 5-FU (50 µg/ml) treatment with or 
without GSH (10 µM).  (F) The levels of HMGB1 in the medium of the cells treated as in E.  **p<.01. 
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Figure 23: Caspase-3 KO does not affect apoptosis or necrosis after TNFα treatment. 
HCT 116 and C3KO cells were treated with TNFα (10 ng) and cyclohexamide (5 µM) for 48h, and 
analyzed by flow cytometry following PI and annexin V staining.  (A)  Fractions of PI+/Annexin V- cells.  (B)  
Fractions of PI+ cells.  (C)  Fractions of Annexin V+ cells. 
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Figure 24: Caspase-3 KO cells die by ROS dependent necrosis. 
(A)  Flow cytometry profiles for C3KO cells stained with PI and annexin V following 48h treatment 
with DMSO, 5-FU (50 µg/ml), GSH (10 µM) or combination of 5-FU and GSH.   (B) Reactive oxygen species 
generation in and C3KO cells expressing a short hairpin construct against RIP1 or scrambled control treated 
for 24h with 5-FU (50 µg/ml). **p<.01 
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3.4.4 Caspase-3 knockdown promotes DNA-damage induced necrosis in colon cancer cells  
We generated stable HCT116 and RKO caspase-3 knockdown (KD) cell lines using shRNA.  5-
FU treatment induced necrosis in caspase-3 KD HCT116 and RKO cells as evident by increased 
PI+/Annexin V- populations, ROS production and HMGB1 release, as well as a steep drop in 
cellular ATP levels (Figures. 25A-F, 26 and 27A).  The increased PI+/Annexin V- population 
was significantly reduced by Nec-1 but unaffected by z-VAD in caspase-3 KD RKO cells 
(Figure 25G).  CPT or Etoposide treatment led to necrosis in caspase-3 KD HCT116 and RKO 
but not in control cells (Figure 25H-I).  These results demonstrate that loss of caspase-3 leads to 
enhanced sensitivity of colon cancer cells to DNA damaging agents via induction of necrosis, 
and caspase-3 is dispensable for DNA-damage induced apoptosis.    
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Figure 25: Caspase-3 KD increased necrosis in response to DNA damage. 
(A)  Stable caspase-3 knockdown in HCT 116 cells was confirmed by western blotting.  (B)  Fractions 
of PI+/Annexin V- cells 48h after 5-FU (50 µg/ml) treatment.  (C)  The levels of HMGB1 in the medium from 
the indicated cells treated as in B.  (D) Stable caspase-3 knockdown in RKO cells was confirmed by western 
blotting.  (E)  Fractions of PI+/Annexin V- cells 48h after 5-FU (50 µg/ml) treatment.  (F)  The levels of 
HMGB1 in the medium from the indicated cells treated as in E.  (G)  Fractions of PI+/Annexin V- cells 48h 
after 5-FU (50 µg/ml) treatment, with or without pan caspase inhibitor z-VAD (20 µM) or necrostatin-1 (Nec-
1, 15 µM).  (G)  Fractions of PI+/Annexin V- RKO cells 48h after CPT (500 nM) or Etoposide (50 µM) 
treatment.  (H)  The levels of HMGB1 in the medium from the indicated RKO cells treated as in H.  **p<.01. 
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Figure 26: HCT116 caspase-3 knockdown cells show increased necrosis following 5-FU treatment. 
(A) Flow cytometry output for HCT116 GFP and caspase-3 KD cells stained for PI and Annexin V 
following 48hr 5-FU (50µg/ml) treatment.   (B) Reactive oxygen species generation in stable HCT116 GFP 
and caspase-3 KD cells treated for 24hr with 5-FU (50 µg/ml). *p<.05, **p<.01 
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Figure 27: RKO caspase-3 knockdown cells show increased necrosis after DNA damage. 
(A)  Cellular ATP levels of RKO GFP and caspase-3 KD cells treated with 5-FU (50 µg/ml) for 48hr. 
(B) Flow cytometry output for RKO GFP and caspase-3 KD cells following 48h treatment with 5-FU (50 
µg/ml), z-VAD (20 µM) and/or Nec-1 (15 µM).  (C) Reactive oxygen species generation in stable RKO GFP 
and caspase-3 KD cells treated for 24hr with 5-FU. **p<.01  (D)   Crystal violet staining of adherent cells 48h 
after CPT (500 nM) or Etoposide (50 µM) treatment.   
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3.4.5 Loss of caspase-3 stabilizes a necrotic complex and RIP1 ubiquitylation 
To better understand how caspase-3 suppresses necrosis, we used immunoprecipitation (IP) 
experiments to examine potential cell death complexes involving RIP1 and caspase-8 in WT and 
C3KO cells after 5-FU treatment.  Caspase-8 pull-down revealed a low level of existing caspase-
8/RIP1/FADD complex in unstressed WT cells, while 5-FU treatment recruited unprocessed 
caspase-3 to this complex (Figure 28A).  Interestingly, RIP1 was not found with caspase-
8/FADD in unstressed C3KO cells, and much higher levels of caspase-8/RIP1/FADD complex 
were found in 5-FU treated C3KO (Figure 28A).  Reciprocal caspase-3 pull-down confirmed 
caspase-3 recruitment to the complex after 5-FU treatment in WT cells, and the full length, but 
not process caspase-3 preferentially binds to caspase-8 (Figure 28B).  The catalytically dead 
mutant C163A was found to effectively bind to this complex after 5-FU treatment in 
reconstituted C3KO cells (Figure 28C).  These findings suggest that caspase-3 recruitment to the 
caspase-8/RIP1/FADD complex facilitates caspase-8 activation and perhaps apoptosis in WT 
cells.   
z-VAD blocked 5-FU-induced apoptosis and caspase-8 processing, but not necrosis, in 
C3KO cells (Figure 19C).  We reasoned that the necrotic complex might be stabilized upon z-
VAD treatment if apoptosis competes away or cleaves components shared by apoptosis and 
necrosis.  The caspase-8/RIP1/FADD complex and polyubiquitylated RIP was drastically 
enhanced in WT cells co-treated with z-VAD and 5-FU, and to a much greater levels in C3KO 
cells (Figure 28D).  Interestingly, z-VAD treatment completely prevented binding of caspase-3 to 
this complex, in WT cells (Figure 28E).  Higher levels of RIP1 ubiquitylation were found in 
unstressed C3KO cells (Figure 28F).  These results suggest caspase-3 ablation or inhibition by z-
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VAD stabilizes the caspase-8/RIP1/FADD complex and caspase-3 acts as negative regulator of 





Figure 28: Loss of Caspase 3 or z-VAD treatment stabilizes the necrotic complex and RIP ubiquitination. 
(A) Analysis of caspase-8 interacting proteins followed by caspase-8 immunoprecipitation in HCT116 
WT and C3KO cells 24h with or without 5-FU (50 µg/ml) treatment.  Input = whole cell lysate. (B)  Analysis 
of caspase-3 interacting proteins followed by caspase-3 IP  in cells treated as in (A).  (C) Analysis of caspase-8 
interacting proteins in C3KO cells reconstituted with C163A mutant treated as in A.  (D) Analysis of caspase-
8 interacting proteins in cells treated as in (A) in the presence of z-VAD (20 µM).  (E) Analysis of caspase-3 
interacting proteins in cells treated as in (A) in the presence of z-VAD (20 µM). (F) Analysis of RIP 




3.4.6 DR5, Caspase-8 and FADD are required for both apoptotic and necrotic cell death 
induced by 5-FU in caspase-3 KO cells 
The above findings suggest removal of caspase-3 switches the apoptotic complex to a necrotic 
one, which likely requires full length caspase-8 (pro-caspase), RIP1 and FADD, for execution 
and lies downstream of death receptor activation.  Knock down of either DR5 or caspase-8 using 
siRNA significantly blocked 5-FU-induced necrosis in C3KO cells measured by increases in the 
PI+/Annexin V- population and HMGB1 release (Figure 29A-C).  We further generated caspase-
3 KD/FADD KO HCT116 cells [153] (Figure 29D), and found FADDKO completely blocked 5-
FU-induced necrosis in C3KD cells (Figure 29E-F).  Knockdown of DR5, caspase-8 or FADD 
KO also blocked apoptosis (Annexin+/PI-), and total cell death (Figure 30).  A better protection 
from 5-FU-induced cell death by FADD KO compared to DR5 or caspase-8 KD was likely due 
to complete elimination of the target.  These results demonstrate the requirement for DR5, 
caspase-8 and FADD in 5-FU induced cell death, and a selective anti-necrosis role of caspase-3. 
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Figure 29: Death receptor 5, caspase-8 and FADD are required for 5-FU induced cell death. 
(A) Knockdown of DR5 or caspase-8 in C3KO cells by siRNA confirmed by western blotting. (B)  
Fractions of PI+/annexin V- cells 48h after 5-FU (50 µg/ml) treatment.  (C) The levels of HMGB1 in the 
medium in cells treated as in (B).  (D)  Stable knockdown of caspase-3 by shRNA in FADD KO cells 
confirmed by western blotting.  (E) Fractions of PI+/annexin V- FADD KO cells 48h after 5-FU treatment.   




Figure 30: DR5, caspase-8, and FADD are required for 5-FU induced cell death. 
(A-B), C3KO cells with DR5, Caspase-8 siRNA.  (A)  Quantification of dead (Annexin V+ or PI+) 
populations in C3KO cells transiently transfected with siRNA against DR5, caspase-8 or a scrambled control 
following 48h treatment with 5-FU (50 µg/ml).  (B)  Quantification of live (PI-/Annex V-) populations in 
C3KO cells transiently transfected with siRNA against DR5, caspase-8 or a scrambled control following 
treatment as in A.  **p<.01.  (C-D), C3KD with or without FADD KO.  (C)  Quantification of dead (Annexin 
V+ or PI+)  populations in HCT116 FADD KO cells with stable expression of a caspase-3 KD construct or 
GFP control following 48h treatment with 5-FU (50 µg/ml).  (D)  Quantification of live (PI-/Annex V-) 
populations in HCT116 FADD KO cells with stable expression of a caspase-3 KD construct or GFP control 
following treatment as in A.  **p<.01 
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3.4.7 Caspase-3 KO tumors show increased response and necrosis to 5-FU in vivo 
Next we determined the role of caspase-3 in the therapeutic responses to 5-FU in mouse 
xenograft experiments.  Equal numbers of WT and C3KO cells were implanted subcutaneously 
on the flanks of seven-week old female nude mice.  Mice with established tumors were treated 
with either 50 mg/kg 5-FU or vehicle every other day for 14 days.  C3KO tumors showed a 
significantly greater response to 5-FU compared to WT tumors (Figure 31A-C).  Tumors were 
harvested at the end of the treatment, and analyzed for histopathology and markers of cell death.  
C3KO tumors exhibited significantly more necrosis with areas of complete loss of cellularity and 
more TUNEL positive cells, compared to WT tumors in the same host (Figures 31D-F and 32).  
These results strongly indicate that loss of caspase-3 enhances tumor responses to 5-FU via 
induction of necrosis in vivo. 
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Figure 31: Caspase-3 KO cells show increased response and necrosis to 5-FU in vivo. 
(A)  The relative growth of tumors compare to the volume before the first 5-FU treatment (day 0, 1). 
The average tumor volume is about 50 mm
3
.  5-FU (50 mg/kg) was given intraperitoneally (I.P)  every other 
day for 14 days.  (B) Representative HCT116 WT and C3KO tumors after the last treatment.  (C) Relative 
volume of HCT116 WT and C3KO tumors after the last treatment. (D)  H&E staining of tumors with 
indicated genotype after the last treatment.  (E) Staining of active caspase-3 and TUNEL in the tumors after 
the last treatment.  (F) Quantization of TUNEL positive cells in HCT116 WT and C3KO xenograft tumors 
with the indicated treatment.  Three tumors were randomly chosen in each group.  **p<.01 
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Figure 32: Caspase-3 KO cells show enhanced responses to 5-FU in vivo. 
Tumor bearing mice were treated as in Figure 8A.  (A)  H&E staining of HCT116 WT tumors at the 





Most cancer therapies promote apoptosis, but an inherent difficulty with this approach is that 
oncogenic alterations often render cancer cells resistant [15, 160, 161].  Therefore, activation of 
alternative cell death pathways is worth exploring.  Molecular mechanisms of programmed 
necrosis have been under intensive investigation, and the best understood is TNFα-induced 
necrosis through both RIP1 and RIP3.  In contrast, very little is known about DNA damage-
induced necrosis [99 , 180].  Our work demonstrates that targeting caspase-3 promotes RIP1- and 
ROS-dependent necrosis in cancer cells in response to genotoxic stress, independent of RIP3.  
RIP3 is expressed in many normal tissues [99] but not in most colon cancer cells or in lung 
cancer cell lines [103], which might explain why cancer cells generally do not undergo necrosis 
in response to TNFα even in the presence of z-VAD.  Caspase-3 KO mice have limited 
abnormality in apoptosis, but were recently found to be more sensitive to DNA damaging agents 
such as UV-B and doxorubicin with a necrosis-like cell death [181], consistent with an anti-
necrotic function of caspase-3.  Therefore, a better mechanistic understanding of RIP3-
independent necrotic cell death triggered by DNA damage could bear important fruits for cancer 
therapy 
To our knowledge this is the first report indicating caspase-3 as an inhibitor of caspase-8 
and RIP1-dependent necrosis induced by DNA damage yet completely dispensable for apoptosis, 
and represents another example of competition between apoptosis and necrosis.  Caspase-3 
recruitment to the caspase-8/RIP1/FADD/caspase-3 complex switches on apoptosis to block 
necrosis (Figure 33).  RIP1 activity is highly regulated by K377 ubiquitylation with a Lysine-63 
linkage leading to its activation and a Lysine-48 linkage leading to proteasome-mediated 
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degradation [182].  Since RIP1 knockdown does not affect apoptosis, one interesting possibility is 
that enhanced RIP1  
 
Figure 33: A model for caspase-3-mediated suppression of DNA-damage induced necrosis. 
The extrinsic pathway and ROS can mediate both apoptosis and necrosis in response to genotoxic 
stress via distinct death promoting complexes.  Loss of caspase 3 shifts the equilibrium to necrotic complex 
containing caspase-8/RIP1/FADD which might involve polyubiquitylation of RIP1.  The apoptotic complex 
containing caspase-3, but not the necrosis complex is sensitive to z-VAD.  Increased expression of death 
receptor and ligand might enhance cell killing in p53 WT cells.   
 99 
ubiquitylation, rather than deubiquitantion [182], in C3KO cells likely promotes necrosis (Figure 
8).  The complex described in our study might be related to the Ripoptosome [146], which contains 
caspase-8/RIP1,/FADD, and can initiate either apoptosis or necrosis depending on the relative 
levels and activation of caspases and inhibitor of apoptosis proteins (IAPs) [144, 146].  Inhibition 
of caspase-8 activity in the Ripoptosome by cFLIP overexpression leads to necrosis [146], while 
activated caspase-8 can cleave RIP1 to inhibit necrosis [168].  Our work also suggests that z-VAD 
functions as an allosteric inhibitor, and specifically prevents caspase-3 recruitment to the caspase-
8/RIP1/FADD complex and its stabilization.  This bears resemblance to Nec-1, an allosteric 
inhibitor of RIP1, that affects both kinase-dependent and -independent functions [183].  These 
findings demonstrate a complex interaction between caspases and RIP1 in regulating cell fate. 
Non-overlapping functions of caspase-3 and caspase-8, or RIP1 and RIP3 are well-
supported by genetic studies.  Caspase-3 knockout mice in the C57BL/6 background are fertile but 
have developmental abnormalities, which is a sharp contrast with the embryonic lethality upon 
gene ablation in Casapse-8, FLIP or FADD via RIP3-dependent necrosis.  On the other hand, RIP1 
KO mice have much more profound immune and survival defects, compared to RIP3 KO mice [99, 
180].  Further investigation will be required to fully understand the manner in which caspase-3 
affects caspase-8 or RIP1 activity and modulates the switch between apoptosis and necrosis.  
Given the important roles of these proteins, more precise genetic manipulation by knocking in 
enzymatic, binding or modification defective alleles in mice and human cancer cells will likely 
provide fundamental insights on cell fate determination. 
Our findings also raise several interesting questions for further investigation.  Severe DNA 
damage can induce caspase-8-dependent and p53-independent apoptosis via a ATM/NF- B /RIP1 
and TNF-  feed forward mechanism in cancer cells [132].  In our model, apoptosis was largely 
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unaffected by the absence of RIP1 or caspase-3 in response to several DNA damaging agents, 
suggesting the intact apoptosis is likely mediated by the ATM/NF- B/RIP1 arm and perhaps 
additional apoptotic complexes such PIDDSome (PIDD/Caspase-2) [93, 184].  In p53 WT cells, 
induction of DR5, DR4 and TRAIL (data not shown) might enhance 5-FU-induced cell death 
(Figure 33), as p53 KO HCT 116 cells are partially resistant [185].  In addition, ROS production 
appears upstream of RIP1, suggesting some necrotic components might be redox sensitive.  The 
downstream events of RIP1 in DNA damage-induced necrosis, and the importance of RIP1 kinase 
and inflammation remain completely unexplored.  Even though RIP3 is not required for DNA-
damage induced necrosis, a role of MLK or PGAM5 [96, 97] has not been excluded. 
Is summary, we have shown that targeting caspase-3 leads to an enhanced response to 
DNA damaging agents through induction of necrosis in colon cancer cells, with unaltered 
apoptotic response.  This necrosis requires caspase-8, RIP1, FADD and DR5 but not RIP3, and 
involves a caspase-8/RIP1/FADD complex.  Therefore, pharmacological targeting of caspase-3 or 




4.0  FUTURE DIRECTIONS 
4.1 IDENTIFY THE ROLE OF CASPASE-3 IN TUMOR METABOLISM 
4.1.1 Investigate the role of caspase-3 on glycolysis and oxidative phosphorylation 
Cancer cells generally exhibit altered metabolic pathways, including increased aerobic glycolysis 
for ATP generation and macromolecule formation, which support high rates of proliferation.  In 
some instances, this is due to mitochondrial respiration injury and hypoxia, frequently leading to 
therapeutic resistance [186].   We witnessed a significant increase in sensitivity to both glucose 
and glutamine deprivation in C3KO cells not seen in WT cells (Figure 11), suggesting alteration 
of glycolytic and glytaminolytic pathways.  While glucose and glutamine addiction in cancer 
cells is not uncommon, seeing increased dependence in C3KO cells brings about many questions 
[47].  Increased glucose dependence could be the result of reduced ability of glucose to enter 
glycolysis or dysfunctional glycolysis such that glucose enters the cycle but is never fully 
processed into pyruvate.  As a result of reduced end product, starving cells would be more 
dependent upon high glucose levels.  Alternatively, increased glucose dependence could be a 
result of the exact opposite; glycolysis is upregulated rather than deficient.  Increased glycolysis 
rates would require an increase in raw materials such as glucose.  Increased glutamine 
dependence suggests an increase in glutaminolysis, an alternative energy pathway often seen in 
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tumor cells [187-189].  Inhibition of glycolysis by use of 2-Deoxy-D-glucose, a glucose 
molecule which has the 2-hydroxyl group replaced by hydrogen causing it to act as a dominant 
negative molecule in glycolysis, would aid in determining whether glycolysis is being increased 
or decreased in C3KO cells.  Furthermore, use of this molecule would help identify the level to 
which alternative energy sources (i.e. glutamine) could compensate for lost glucose.  A better 
understanding of the alterations in glucose and glutamine metabolism will help delineate the role 
of caspase-3 in metabolism.   
In addition to altered glucose and glutamine dependence we witnessed significant changes in 
oxidative phosphorylation in C3KO cells.  Namely, C3KO cells showed reduced ability to 
perform oxidative phosphorylation as shown by decreased maximum respiration and spare 
respiratory capacity (Figure 9).  Extensive studies will need to be performed to identify the 
defective complex(es) leading to reduced respiration.  One potential player is the mitochondria 
fusion protein mitofusin 2.  Levels of MFN2 were significantly reduced in C3KO cells (Figure 
10).  Studies are currently underway to determine if reconstitution of MFN2 restores 
mitochondrial morphology/function to WT levels.  Identifying caspase-3 as having a role in 
cancer cell proliferation and metabolism is exciting in that it provides an opportunity to slow 
tumor growth.  In vivo studies suggest that if an inhibitor of caspase-3 were successfully 
generated it could reduce tumor size by more than half (Figure 14).  There is potential for using a 
caspase-3 inhibitor with conventional chemotherapy to reduce tumor volume to a point where 
surgical intervention becomes a viable option.  Identifying the role caspase-3 has on 
mitochondria morphology and cellular metabolism could have an incredible impact on 
development of next generation therapies.   
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4.1.2 Identify the effects of caspase-3 loss on cell survival and proliferation in other 
cancers. 
In chapter two we highlighted the consequence of caspase-3 loss on cell survival and 
proliferation in HCT116 colon cancer cells (Figures 5, 6 and 7).  We were able to replicate these 
results in other colon cancer cell lines but have not expanded beyond that (Figures 12 and 13).  
One of the first steps in identifying if the phenomenon we see is relevant to cancer as a whole or 
simply CRC is repeating experiments in other cancer cell models.  A logical first step in this 
direction would be using MCF 7 breast cancer cells as they harbor a deletion mutation resulting 
in loss of exon 3 and as a result do not express caspase-3 [190, 191].  If reconstitution of 
caspase-3 in MCF 7 leads to an increase in cell survival and proliferation it would warrant 
investigating additional models.   
 
4.2 FURTHER DELINEATE THE ROLE OF CASPASE-3 IN NECROSIS 
4.2.1 Identify all components of cell death complex 
Having identified a role for caspase-3 in necrosis following treatment of HCT116 cells with 
DNA damaging agents, we investigated potential cell death protein complexes involved (Figures 
19-21 and 28).  We were able to positively identify caspase-8, FADD and RIP1 as binding 
partners with caspase-3 following treatment in WT cells (Figure 28).  The same complex minus 
caspase-3 formed in C3KO cells following treatment.  While our data suggest that the same 
 104 
complex is involved in both apoptosis and necrosis, and the pathway initiated is dependent upon 
the presence of caspase-3, we have yet to definitively confirm this.   We attempted to address 
this question through FADD knockout experiments and demonstrated nearly complete loss of 
cell death in these cells (Figures 29 and 30).  However, an inherent difficulty in answering this 
question is the fact that caspase-8 and FADD are required proteins for many cell death 
complexes including the DISC, Necrosome and Ripoptosome (Figure 4).  Another approach for 
identifying the role of cell death complexes present in our study would be immunoprecipitation 
of the complex followed by mass spectrometry to identify other proteins present.  While this 
method is valid, it is time and cost intensive.  A third option that we are currently undertaking is 
gel filtration chromatography.  This technique allows for identification of protein complexes as 
proteins bound to one another will elute from the column in the same fraction.  Discovery of 
additional proteins bound to caspase-3, caspase-8, FADD and RIP1 following drug treatment in 
both C3KO and WT HCT116 cells will allow us to further categorize the protein complex we are 
dealing with and determine the consequences of manipulating it.    
4.2.2 Verify binding locations and partners of caspase-3 
Since we have demonstrated that caspase-3 is a critical part of pro-death protein complexes, the 
next logical step would be to identify caspase-3 binding partners and their specific binding 
domains.  Using C3KO cells reconstituted with caspase-3 expression constructs containing point 
mutations in potential binding domains coupled with immunoprecipitation of potential binding 
partners and immunoblotting, should allow us to identify putative caspase-3 binding partners.  
Verification of these interacting proteins will help us further understand how caspase-3 is 
dictating activation of certain cell death pathways.   
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4.2.3 Establish how posttranslational modification of RIP1 affects cell death 
The literature surrounding RIP1 and its plethora of roles in cell biology has been expanding 
exponentially in recent years.  RIP1 has been shown to have roles in cell proliferation, 
inflammation, immune response and cell death [130, 192].   This ability to function in numerous 
processes is due to RIP1’s ability to undergo various posttranslational modifications.  For 
instance, phosphorylation via RIP3 or autophosphorylation leads to increased necrosis.  
Alternatively, ubiquitination can lead to inflammation, cell proliferation, or proteosomal 
degradation.  Our data suggests that RIP ubiquitination is increased in 5-FU treated C3KO cells 
indicating either activation of the inflammatory response or RIP1 is being marked for 
degradation (Figure 28).   However, we have yet to verify if it is K63 or K48-linked 
ubiquitination.  K63-linked ubiquitin would suggest that the NF-κB response is activated and 
inflammation may be occurring.  This would be detrimental for patient therapy.  Conversely, 
K48-linked ubiquitin would suggest that RIP1 has been marked for degradation by the 
proteasome.  While degradation of RIP1 does not imply cell death will cease as we witnessed 
cell death in RIP1 KD cells (Figure 22), it does suggest the involvement of a RIP1-independent 
cell death complex.  Classification of RIP1’s ubiquitination/phosphorylation status will give us a 
better understanding of additional pathways/cell responses unique to C3KO cells.  
4.2.4 Identify potential cell death pathway components 
Following identification of the cell death complex involved in 5-FU induced C3KO cell death, 
we looked to further characterize the death response by knocking out potential downstream 
signaling molecules.  Both transient knockdown of DR5 and caspase-8, in addition to knockout 
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of FADD, resulted in reduced apoptosis and necrosis (Figures 29 and 30).  However, stable 
knockdown of RIP1 did not result in reduced cell death (Figure 22).  While these data provide a 
foundation for understanding the signaling pathways involved in C3KO cell death, there is still 
much to be uncovered.  The necessity of DR5 and caspase-8 suggests that the extrinsic apoptotic 
response is activated in response to 5-FU, but this will need to be confirmed through knockout of 
other known extrinsic pathway proteins.  Furthermore, experiments will need to be conducted to 
determine activation of known DR5 downstream pathways including the JNK, p38 and NF-κB 
pathways, among others.   Identification of pathway activation and the proteins involved in 5-FU 
mediated C3KO cell death will provide better understanding of the consequences of caspase-3 
loss in cancer cells.   
4.2.5 Establish if p53 is required for cell death in C3KO cells 
It is well established that p53 is one of the most commonly mutated genes in cancer[27].  
Mutated p53 can result in a diminished or absent DNA damage response and reduced cell death 
[185].  While p53 is commonly mutated in CRC, the model we used for our experiments, 
HCT116 contains two wild-type alleles [30].  Additionally, the cell line we verified work in, 
RKO also contains WT p53.  In light of this, the question of whether or not p53 is required for 
the 5-FU response we see needs to be answered.  Literature outlining the role of the PIDDosome 
in response to 5-FU in HCT116 suggests that in the absence of p53, 5-FU does not induce cell 
death [93, 94].  In support of this, our results show that p53 and a number of its downstream 
targets are induced in response to 5-FU treatment in both WT and C3KO cells.  While it is our 
hypothesis that the cell death we witnessed is p53-dependent, further experimentation in p53 KO 
HCT116 and RKO colon cancer cells will need to be completed.   
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4.2.6 Expand on chemotherapeutics and cell models used 
While our data show conclusively that loss of caspase-3 leads to increased sensitivity to 5-FU 
through activation of necrosis in HCT116 cells, it fails to show this phenomenon is relevant to 
cancer models beyond CRC.  Further experimentation in additional cancer models would 
elucidate the potential broad range of our findings.  Moreover, treatment of C3KO cells with 
additional classes of drugs beyond DNA-damaging agents will help identify the role of caspase-3 
in other cell death responses.  
 Identifying caspase-3 as a key mediator in the decision for a cell to die by apoptosis or 
necrosis following DNA damage is an exciting finding that could potentially have extensive 
applications in future therapeutics.  Additional future studies will help determine if our findings 
are able to be applied strictly to CRC or more globally to cancer as a whole.  Regardless of the 
outcome, our data show caspase-3 to be a critical regulator of cell survival, proliferation and 
death pathway activation, warranting further investigation and consideration for future 






Table 4: In-text abbreviations 
Abbreviation Full Name 
5-FU 5-fluorouracil 
A20 TNFAIP3 Interacting Protein 2 
AAV Adeno-associated virus 
AIF Apoptosis-inducing factor 
AKT V-Akt murine thymoma viral oncogene homolog 1 
APAF-1 apoptotic peptidase activating factor 1  
APC Adenomatous polyposis coli  
ATP Adenosine triphosphate 
Bad BCL2-associated agonist of cell death 
Bak BCL2-antagonist/killer 1  
Bax BCL2-associated X protein  
Bcl-2 B-cell CLL/lymphoma 2  
Bcl-xl BCL2-associated agonist of cell death  
BH3 Bcl-2 homology domain 3 
Bid BH3 interacting domain death agonist  
Bik BCL2-interacting killer  
Bim BCL2-like 11 
BIR Baculovirus Interacting Repeat 
Bmf Bcl2 modifying factor  
BMPR1A Bone morphogenetic protein receptor, type IA  
Bok BCL2-related ovarian killer  
BSA Bovine serum albumin 
C163A Catalytically dead C163A mutated caspase-3 expression construct 
C3 Caspase-3 
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Table 4 continued 
C3KO Caspase-3 knockout cells 
CARD Caspase recruitment domain 
CASP3 Caspase-3 
c-FLIP CASP8 and FADD-like apoptosis regulator 
cIAP1 Cellular inhibitor of apoptosis 1 
cIAP2 Cellular inhibitor of apoptosis 2 
CPT Camptothecin 
CRC Colorectal cancer 
CYLD Cylindromatosis 
DIABLO IAP-binding mitochondrial protein  
DISC Death-inducing signaling complex 
DR5 Death receptor 5 
EGFR Epithelial growth factor receptor 
EMT Epithelial-mesenchymal transition  
EndoG Endonuclease G  
EPCAM Epithelial cell adhesion molecule  
ERK Extracellular-signal-regulated kinase 
Etop Etoposide 
FADD Fas (TNFRSF6)-associated via death domain  
FAP Familial adenomatous polyposis 
FAS TNF receptor superfamily, member 6 
FAS-L FAS ligand 
FDA Food and Drug Administration 
FH Fumurate hydratase 
FLC3 Full length caspase-3 expression construct 
Foxo3a Forkhead box O3, a 
GADD45 Growth arrest and DNA-damage-inducible protein  
GFP Green fluorescent protein 
GIST Gastrointestinal stromal tumors 
GLUD1 Glutamate dehydrogenase 1 
GLUL  Glutamate-ammonia ligase  
GTP Guanosine triphosphate 
H2AX H2A histone family, member X  
HBSS Hank's buffered salt solution 
HMGB1 High mobility group box 1  
HRP Horse radish peroxidase 
Htra2 HtrA serine peptidase 2  
IAP Inhibitor of apoptosis protein 
IDH1 Isocitrate dehydrogenase I  
IGF-BP3 Insulin-like growth factor binding protein 3  
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Table 4 continued 
JNK c-Jun N-terminal kinase 
JPS Juvenile polyposis syndrome 
KIT v-kit Hardy-Zuckerman 4 feline sarcoma viral oncogene homolog  
KRAS v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog  
LC3 microtubule-associated protein 1 light chain 3 gamma 
MAP2K4 MAPK kinase 4 
MAP3K5 Mitogen-activated protein kinase kinase kinase 5 
MAPK Mitogen-activated protein kinase 1  
Mcl-1 Myeloid cell leukemia sequence 1 (BCL2-related)  
MFN2 Mitofusin 2 
MLH1 MutL homolog 1, colon cancer, nonpolyposis type 2 (E. coli)  
MLKL Mixed lineage kinase domain-like  
MOMP Mitochondrial outer membrane potential 
MSH2 MutS homolog 2, colon cancer, nonpolyposis type 1 (E. coli)  
MSH6 MutS homolog 6 (E. coli)  
mTOR Mechanistic target of rapamycin  
MYC v-myc myelocytomatosis viral oncogene homolog (avian)  
MYH Myosin, heavy chain 1, skeletal muscle, adult  
NADH Nicotinamide adenine dinucleotide 
Nec-1 Necrostatin-1 
NEMO NF-kappa-B essential modulator 
Neo Neomycin 
NF-κB Nuclear factor of kappa light polypeptide gene enhancer in B-cells  
Noxa Phorbol-12-myristate-13-acetate-induced protein 1 
NSAID Nonsteroidal anti-inflammatory drug 
omi HtrA serine peptidase 2  
p21 Cyclin-dependent kinase inhibitor 1 
p38 Mitogen-activated protein kinase 14 
p53 Tumor protein p53  
p65 Nuclear factor of kappa light polypeptide gene enhancer in B-cells  
PBS Phosphate-buffered saline 
PDGFRA Platelet-derived growth factor receptor, alpha polypeptide  
PGAM5 Phosphoglycerate mutase family member 5  
PI Propidium iodide 
PI3K Phosphoinositide-3-kinase 
PIDD p53-induced death domain protein  
PIK3C2G PI3K, class2, gamma polypeptide 
PIK3R2 Phosphoinositide-3-kinase, regulatory subunit 2 
PKM2 Pyruvate kinase muscle form 2 
PMS2 Postmeiotic segregation increased 2  
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Table 4 continued 
PRR Pathogen recognition receptors 
PTEN Phosphatase and tensin homolog  
PUMA p53 upregulated modulator of apoptosis 
PYGL Phosphorylase glycogen liver 
RAF v-raf-1 murine leukemia viral oncogene  
RAIDD CASP2 and RIPK1 domain containing adaptor with death domain  
RIP1 Receptor (TNFRSF)-interacting serine-threonine kinase 1  
RIP2 Receptor (TNFRSF)-interacting serine-threonine kinase 2 
RIP3 Receptor (TNFRSF)-interacting serine-threonine kinase 3 
RIPA Radio-Immunoprecipitation Assay Buffer 
ROS Reactive oxygen species 
RYK Tyrosine receptor kinase 
SDH Succinate dehydrogenase 
sh Small hairpin 
si Small interfering 
SMAC Secondary mitochondrial activator of cytochrome c 
SMAD4 SMAD family member 4  
STK11 Serine/threonine kinase 11  
STK33 Serine threonine kinase 33 
TAB1 TGF-beta activated kinase 1/MAP3K7 binding protein 1 
TAB2 TGF-beta activated kinase 2/MAP3K7 binding protein 2 
TAK1 Nuclear receptor subfamily 2 group C member 2 
tBid Truncated bid 
TBST Tris-buffered saline/Tween 20 
TCA Tricarboxylic acid cycle 
TGFBR1 Transforming growth factor beta receptor 1  
TGFβ Transforming growth factor, beta  
TNFR Tumor necrosis factor receptor 
TNF-α Tumor necrosis factor, alpha 
TOR Target of rapamycin  
TP53 Tumor protein p53  
TRADD TNFRSF1A-associated via death domain  
TRAF2 THF receptor associated factor 2 
TRAIL1 TNF-related apoptosis-inducing ligand receptor 1 
TRAIL2 TNF-related apoptosis-inducing ligand receptor 2 
TSP1 Spermatogenic leucine zipper 1  
TUNEL Terminal deoxynucleotidyl transferase dUTP nick end labeling 
VEGF Vascular endothelial growth factor 
WNT Wingless-type MMTV integration site family 
XIAP X-linked inhibitor of apoptosis  
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CONTRIBUTIONS OF KIT AND ABL1 TO THE THERAPEUTIC RESPONSE OF GIST 
CELLS TO IMATINIB MESYLATE (GLEEVEC®) 
B.1 ABSTRACT 
Gastrointestinal stromal tumors (GISTs) are the most common mesenchymal tumors of the 
gastrointestinal tract.  Most GISTs are caused by activating mutations in the KIT receptor 
tyrosine kinase gene allowing for their effective treatment with the small molecule kinase 
inhibitor imatinib mesylate (IM).  IM is an inhibitor of KIT as well as ABL1, a kinase that is 
constitutively activated in chronic myeloid leukemia (CML). This study was designed to 
determine whether GISTs express both KIT and ABL1 and their respective contributions to the 
therapeutic response of GISTs to IM. Having shown through IHC that GISTs express both KIT 
and ABL1, we aimed to dissect the contributions of each to GIST cell proliferation/survival 
through siRNA-mediated knockdown. As expected, siRNA-mediated knockdown of KIT led to 
reduced cell proliferation and increased apoptosis in GIST882 cells; while siABL1 showed little 
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effect. Knocking down KIT and ABL1 simultaneously led to a reduced apoptotic response when 
compared to siKIT alone. To determine the cause of apoptosis attenuation in KIT-and ABL1-
deficient cells, cell lysates were made after siRNA transfection and analyzed for signaling 
mediators and regulators of cell cycle and apoptosis by immunoblotting. Knockdown of KIT led 
to inhibition of downstream signaling as well as cell cycle arrest and apoptosis. These effects 
were not present after siABL1. Unexpectedly, ABL1 knockdown led to a substantial increase in 
activated and total AKT. To dissect the pathway leading to increased AKT activation after 
siABL1, we examined upstream signaling regulators of AKT and found increased PDK1 
phosphorylation.  
In conclusion, we have shown ABL1 to be expressed in a GIST tissue microarray. 
Whereas knockdown of KIT showed expected results with respect to cellular proliferation and 
apoptosis, combined knockdown of KIT and ABL1 attenuated the apoptotic response seen by 
siKIT. Immunoblot analysis of whole cell lysates following ABL1 knockdown showed increased 
levels of activated and total AKT. We hypothesize these levels are a result of elevated active and 
total PDK1 levels.  
B.2 BACKGROUND 
B.2.1 Gastrointestinal stromal tumors (GIST) are the most common mesenchymal tumor 
of the gastrointestinal (GI) tract. 
In the past GISTs were viewed as a highly treatment-refractory sarcoma with fewer than 10% of 
patients responding to conventional radio- and chemotherapy [193, 194].  Until the introduction 
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of targeted small kinase inhibitors, the only treatment option for non-responsive tumors was 
surgery [195].  GISTs arise from the bowel wall in the GI tract with the stomach and small 
intestine being the most frequently affected areas [196].   
B.2.2 GISTs arise from interstitial cells of Cajal (ICCs) 
Until the 1990’s GISTs were often misdiagnosed as leimyosarcomas [197].  At this time 
investigators noticed similarities between GISTs and interstitial cells of Cajal (ICCs).  ICCs are 
cells located in the muscularis propria around the myenteric plexus throughout the GI tract, 
serving as pacemakers for peristaltic contraction [198-201].  Differentiation and proliferation of 
ICCs are critically dependent on expression of the KIT receptor tyrosine kinase (RTK) [199].  
Hypothesizing that GISTs arise from the KIT-dependent ICC lineage and that oncogenic KIT 
mutations were known to be found in various human tumors [202-204] Hirota et al. investigated 
whether KIT activating mutations might be significant in GIST pathogenesis. They demonstrated 
high KIT expression in GISTs and found genomic mutations in KIT exon 11. KIT genomic 
mutations were found to be associated with constitutive activation of the KIT kinase function in 
vitro [198]. These findings have been confirmed in several subsequent studies encompassing 
hundreds of GISTs, and it is now known that KIT genomic mutations are key events in GIST 
pathogenesis (Figure 34) [205-211]. 
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Figure 34: Physiologic KIT signal transduction. 
KIT activation in non-neoplastic cells is triggered by binding of the dimeric KIT ligand stem cell 
factor (SCF) leading to homodimerization of two KIT molecules. This is accompanied by structural changes 
in the receptor resulting in activation of the KIT kinase domain. Activated KIT then cross phosphorylates 
tyrosine residues in the associated homodimer partner, leading to additional KIT structural alterations, and 
further activation of the receptors. Phosphorylated tyrosine residues on KIT serve as binding sites for various 
cell signaling proteins. These proteins include members of the RAS/RAF/MAPK and the PI3K/AKT 
pathways, which are regulated by binding of GRB2 and PI3-K to the phosphorylated forms of KIT tyrosine 
residues Y703 and Y721, respectively. Furthermore, the signal transducer and activator of transcription 
(STAT) family of proteins, namely STAT1, STAT3 and STAT5 have been implicated in KIT signaling. 
Ultimately, the phosphorylated KIT receptor stimulates intracellular signaling pathways controlling cell 
proliferation, adhesion, apoptosis, survival and differentiation. Importantly, downstream signaling mediated 
by oncogenically activated KIT in GISTs differs from physiologic KIT signaling. 
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B.2.3 Structure and Function of KIT 
KIT is a member of the type III receptor tyrosine kinase family [212].  KIT is composed of an 
extracellular ligand-binding domain containing five immunoglobulin-like repeats, a 
transmembrane domain, a juxtamembrane domain, and a cytoplasmic kinase domain (Figure 35) 
[213, 214].  KIT is physiologically expressed in hematological stem cells, mast cells, 
melanocytes, germ cells and ICC [199, 215-218].  KIT has known roles in cellular survival, 
proliferation and migration.  Stem cell factor (SCF) is the endogenous ligand for KIT and 
binding induces receptor dimerization and trans-phosphorylation resulting in full activation [219-
223].  Oncogenic KIT is constitutively active without ligand stimulation and activates both pro-
survival and anti-apoptotic pathways (Figure 34) [224, 225].   
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Figure 35: Structure of the receptor tyrosine kinase (RTK) KIT 
KIT is the cellular homolog of the Hardy-Zuckerman 4 feline sarcoma virus oncogene v-KIT. It 
belongs to the type III family of RTKs. These RTKs are characterized by five extracellular IgG-like loops and 
a split kinase domain where the ATP-binding and the phosphotransferase regions are separated by a short 
polypeptide kinase insert. The KIT ligand, stem cell factor (SCF), binds to the extracellular region and leads 
to receptor dimerization. The juxtamembrane domain is important for negative regulation of activation and 
has autoinhibitory function. Mutations within KIT most commonly affect exon 11. Additionally mutations 
have been found in exons 9, 13 and 17. 
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B.2.4 KIT mutations in GISTs 
Activating mutations of KIT are present in up to 85% of GISTs with the most frequent mutations 
being detected in KIT exon 11 affecting the juxtamembrane region of the protein [226]. The exon 
11 mutations are heterogeneous, including deletions of various sizes, insertions, and point 
mutations. In wild-type KIT the juxtamembrane domain forms an alpha helix structure that 
provides an auto-inhibitory function.  Loss of this interaction due to mutation leads to 
constitutive kinase signaling [227]. Approximately 15% of GISTs have mutations in KIT exon 9.  
Mutations in this exon commonly involve duplication of the alanine and tyrosine at position 504 
[208].  Additionally there are mutations involving KIT exons 13 and 17, corresponding to the 
ATP-binding and phosphotransferase domains of the tyrosine kinase region, respectively [207, 
208, 210].   
Despite the fact that KIT mutations in GISTs are found in different parts of the gene 
therefore affecting various domains of the protein, all of them lead to constitutive, ligand-
independent activation of KIT [209].  Up to 20% of GISTs do not contain KIT mutations [228]; 
of this subset 30% harbor mutation in platelet-derived growth factor receptor alpha (PDGFRA).  
PDGFRA mutations are found predominately in exons 12 and 18 which correspond to exons 11 
and 17 of KIT, respectively [229].  Similar to KIT mutations, PDGFRA mutations lead to 
constitutive, ligand-independent kinase activation. Furthermore, KIT and PDGFRA mutations 
appeared to be alternative and mutually exclusive oncogenic events [229].  
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B.2.5 The small molecule kinase inhibitor, imatinib mesylate 
Imatinib mesylate (Gleevec; IM) is a small molecule kinase inhibitor that was originally FDA-
approved to target the BCR-ABL fusion oncoprotein that is generated by the t(9;22) Philadelphia 
chromosome in chronic myeloid leukemia (CML) [230]. Imatinib is a competitive inhibitor of 
ATP and blocks kinase enzymatic activity.  It should be noted that due to conformational 
changes upon activation, imatinib is only able to bind kinases in their inactive form [231].  
Because imatinib is not entirely specific in its binding, it not only inhibits phosphorylation of the 
ABL kinase but also of the KIT and PDGFR kinases [232].  
Imatinib is the first-line therapy for patients with metastatic or inoperable GISTs [233-235].  
It has been shown that up to 85% of patients benefit from imatinib therapy [234].  Upon initial 
treatment patients not responding to imatinib are regarded as having primary resistance.  These 
patients often have exon 9 mutations or no known mutation in KIT (wild-type).  Within 2 years 
of treatment greater than 50% of patients develop resistance mostly due to secondary mutations 
in the KIT kinase. Secondary mutations in the KIT kinase involve either the ATP binding pocket 
of the kinase domain (exons 13, 14) or the kinase activation loop (exons 17, 18).  Secondary 
kinase mutations occur more frequently in GISTs with exon 11 primary mutations.  The 
underlying mechanism for imatinib resistance varies between secondary mutations.  Mutations in 
the ATP binding pocket inhibit the binding of imatinib.  A common ATP binding pocket 
mutation is the T670I “gatekeeper” mutation.  Homologous mutations are found in BCR-ABL as 
well as PDGRFA [236].  Secondary mutations involving the activation loop of KIT aid in 
stabilizing the kinase in its active conformation.  This is detrimental for imatinib as it is unable to 
recognize the active conformation of kinases [226].  In addition to secondary mutations, GISTs 
have been shown to develop imatinib resistance through genomic amplification of KIT and/or 
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becoming hemi- and/or homozygous for the primary KIT mutation by deleting the remaining 
wild-type KIT allele [237, 238].   
If a patient progresses while on imatinib therapy, first response is to increase drug dose as 
tolerated.  In a phase III trial, 33% of patients showed improved imatinib response when the dose 
was increased from 400 mg to 800 mg.  It is thought that increased dosage is capable of 
counteracting decreased binding affinity associated with ATP bonding pocket mutations.  If a 
patient fails to respond to increased imatinib dosage, sunitinib is the second line of therapy. 
Sunitinib (Sutent®, Pfizer) is a small molecule kinase inhibitor that inhibits KIT, PDGFRA, 
VEGF and FLT3.  Similarly to imatinib, sunitinib cannot inhibit activated KIT and therefore is 
ineffective against activation loop mutations.  Furthermore, sunitinib resistance is frequent and 
generally occurs within six months [226].  For a patient unresponsive to sunitinib, there are no 
therapeutic options beyond surgical removal of tumors.   
B.2.6 Function and inhibition of ABL 
The cause behind chronic myeloid leukemia (CML), BCR-ABL is the target protein imatinib-
mesylate was originally developed for.  Fusion of the breakpoint cluster region (BCR) on 
chromosome 9 with ABL on chromosome 22 results in the t(9;22) Philadelphia chromosome 
fusion protein BCR-ABL.  In BCR-ABL, full length wild-type ABL is retained with exception to 
a small N-terminal region upstream of the SH3 domain.  Fusion of ABL with BCR disrupts auto-
inhibitory interactions in ABL and results in a constitutively active kinase [239].  ABL is a 
ubiquitously expressed kinase that localizes to the cell nucleus, plasma membrane and actin 
cytoskeleton [240-242]. Two isoforms (1a, 1b) of ABL originate from alternate splicing of a 
single gene.  ABL 1b differs from 1a in that it contains a myristoyl fatty acid moiety binding 
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region at the N-terminus and it is more highly expressed. This myristoyl group has been shown 
to interact with the catalytic domain in an auto-inhibiting fashion [243, 244]. The amino-
terminus of ABL is highly similar in structure to the SRC family kinases (SFK) (Figure 36) 
[245].  ABL has multiple sites of activation including Y245 and Y412 (Figure 36).  ABL has 
been shown to play a role in signaling pathways activated by growth factors, oxidative stress, 
ionizing radiation and integrin stimulation [246].  Activation of nuclear ABL in response to 
DNA double strand breaks induces apoptosis, while activation of the cytoplasmic/membrane 
pool promotes proliferation and migration [247].  ABL has been shown to be involved in the 
development of multiple normal tissues as well as several malignancies [241, 248, 249].  While 
BCR-ABL has been shown to have properties similar to oncogenic KIT, the non-translocated 
wild-type ABL has vastly different functions. Since ABL is a ubiquitously expressed kinase, we 
hypothesize it is likely expressed in GIST.  Because imatinib inhibits both KIT and ABL, we aim 
to dissect the relative contributions of KIT and ABL inhibition in imatinib-induced apoptosis 




Figure 36: ABL and SFK structure. 
ABL1b and SRC family kinases (SFK) both contain SH2, SH3 and Kinase domains. Additionally 
both are myristoylated at the N-terminus. ABL1b differs from SFKs in its C-terminal tail. Phosphorylation 
sites are indicated in red. U. Unique region 
 
Figure 37: Imatinib inhibits both KIT and ABL 
GISTs are caused by activating mutations in the KIT gene. Activated KIT leads to increased 
proliferation through PI3K and MAPK signaling. KIT activity is inhibited by imatinib mesylate (IM), 
however IM is known to inhibit both KIT and ABL. ABL is a ubiquitously expressed protein involved in the 
DNA damage response within the nucleus and cytoskeleton reorganization within the cytoplasm. Little is 




Although 85% of patients benefit from the small kinase inhibitor, imatinib mesylate initially, 
more than 50% will develop drug resistance within two years of treatment. In addition to drug 
resistance there is a substantial amount of residual tumor mass following imatinib therapy.  
Imatinib mesylate has been shown to inhibit ABL as well as KIT. Better understanding of 
imatinib’s mode of action and the relative contribution of KIT and ABL inhibition in imatinib-
treated GISTs will help to develop novel and better treatment strategies.  
B.3 MATERIALS AND METHODS 
B.3.1 Cell culture 
The imatinib-sensitive human GIST cell line GIST882 (kindly provided by Jonathan A. Fletcher, 
Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, USA) were derived 
from untreated metastatic GISTs and maintained in RPMI1640 (supplemented with 15% fetal 
bovine serum, FBS; 1% L-glutamine, 50 U/ml penicillin, 50 µg/ml streptomycin, 0.5 µg/ml 
amphotericin B). GIST882 cells carry a homozygous mutation in KIT exon 13 (K642E) (39).  
Imatinib-sensitive GIST-T1 cells (a generous gift of Dr. Takahiro Taguchi, Kochi Medical 
School, Kochi, Japan) were maintained in DMEM supplemented with 10% fetal bovine serum 
(FBS, Mediatech, Herndon, VA), 5 ml L-Glutamine, 50 U/ml penicillin (Cambrex, Walkersville, 
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MD) and 50 µg/ml streptomycin (Cambrex) at 37°C/5% CO2.   Human chronic myeloid 
leukemia K562 cells were obtained from the American Type Culture Collection (Manassas, VA, 
USA) and maintained in the same manner as GIST882. 
B.3.2 Immunohistochemistry 
For immunohistochemistry a TMA containing 28 GIST samples (in collaboration with Dr. Shih-
Fan Kuan, Department of Pathology, University of Pittsburgh School of Medicine, Pittsburgh, 
PA; IRB #0509050) was incubated overnight at 65°C.  Slides were deparafinized in xylene, 
rehydrated in ethanol and washed in dH2O.  Slides were pretreated by heating to 95°C 3 times in 
buffer citrate (0.1M citric acid, 0.1M sodium citrate).  Slides were then cooled and washed with 
dH2O followed by PBS.  Slides were then  stained using “Histo-Plus 3
rd
 Generation IHC Kit” 
(Invitrogen, Carlsbad, CA) according to manufacturer’s recommendations.  Rabbit polyclonal 
antibody against c-ABL Y412 (Cell Signaling) was used to access activation loop 
phosphorylation.  K562 cells embedded in paraffin served as positive control for constitutive 
BCR-ABL activation.    
B.3.3 Transient transfection 
GIST882 cells were transfected with siRNA targeting a single kinase alone (Qiagen, Valencia, 
CA) or in combination (SMARTpool, Dharmacon) using Amaxa nucleofection technology as 
recommended by the manufacturer.  K562 cells were maintained in RPMI-1640 as described 
above until 50% confluent. Media was then be removed and replaced with antibiotic free RPMI-
1640 containing 3µl HiPerFect transfection reagent (Qiagen) and 5 µl siRNA diluted in 100 µl 
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serum free media.  Cells were transfected with siRNA against KIT, ABL, a combination of KIT 
and ABL or a non-coding siRNA control (Dharmacon, Lafayette, CO).  Cells were then grown at 
37°C/5% CO2 for 72 h before being lysed. 
B.3.4 In vitro apoptosis and proliferation assays 
Apoptosis and cell viability studies were performed using the Caspase-Glo and CellTiter-Glo 
luminescence-based assays (Promega, Madison, WI, USA) as described previously (13). For 
these studies, cells were plated in a 96-well flat-bottomed plate (Perkin Elmer, San Jose, CA), 
cultured for 24 h and then incubated for 48 h (Caspase-Glo) or 72 h (CellTiter-Glo) with the 
respective compounds at indicated concentrations or DMSO-only solvent control. Luminescence 
was measured with a BioTek Synergy 2 Luminometer (BioTek, Winooski, VT), and the data 
were normalized to the DMSO-only control group.  
B.3.5 Immunoblot 
Protein lysates of GIST monolayer cultures (24) were prepared by washing twice with PBS and 
then scraping cells into RIPA buffer [1% NP40, 50 mmol/L Tris-HCl (pH 8.0), 100 mmol/L 
sodium fluoride, 30 mmol/L sodium pyrophosphate, 2 mmol/L sodium molybdate, 5 mmol/L 
EDTA, and 2 mmol/L sodium orthovanadate] containing protease inhibitors (10 μg/mL 
aprotinin, 10 μg/mL leupeptin, and 1 μmol/L phenylmethylsulfonyl fluoride). Whole cell lysates 
were then incubated for one hour with shaking at 4°C and then cleared by centrifugation for 30 
minutes at 14,000 rpm at 4°C. Protein concentrations were determined by the Bradford assay 
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(Biorad, Hercules, CA). 25 µg of protein for each sample was separated on a 4-12% Bis-Tris gel 
and blotted onto a nitrocellulose membrane. 
. Primary antibodies used for immunoblotting include: S6K, p-S6K (T389), (Abcam); 
H2AX, (Bethyl); p-ABL1 (Y412), p-AKT (S473), p-AKT (T308), AKT, p-KIT (Y719), PDK1, 
p-PDK1 (S241), p-PI3K (Y458), PI3K, p-PTEN (S380), PTEN, (Cell Signaling); KIT, (Dako); 
p-KIT (Y703), PARP, (Invitrogen); ABL1, (Santa Cruz); β-Actin, (Sigma); and p-H2AX (S139), 
(Upstate).   
B.3.6 Statistical analysis 
Statistical significance was assessed using Student's t test for independent samples and the 
Mann-Whitney U test for not normally distributed samples (VassarStats, http://vassarstats.net). P 
values ≤0.05 were considered significant.  
B.4 RESULTS 
B.4.1 ABL is expressed in GIST 
In an effort to determine the effects of inhibiting ABL in GIST we first tested whether ABL is 
expressed in GISTs by staining a tissue microarray containing 28 GISTs for ABL by 
immunohistochemistry.  Individual cores were assessed for ABL and positive staining intensity 
was scored as follows: 1 (weak), 2 (medium), 3 (strong).  Most GISTs (78%) were positive for 
ABL.  The majority of positive stains were weak to medium intensity with staining found 
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predominately in the cytoplasm. All assessable cores were positive for KIT (Figure 38). Having 
shown that most GISTs in fact do express ABL as well as KIT, we aimed to dissect the relative 







Figure 38: Most GISTs express ABL 
Immunohistochemical staining of a tissue microarray containing 28 GISTs showed high levels of KIT 
in all assessable samples (left panel, table). Comparatively, ABL1 was present in 78% of GISTs (right panel, 
table). Staining intensity was scored as 1 (weak), 2 (medium) or 3 (strong). Not ass., not assessable. 
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B.4.2 Dual knockdown of both KIT and ABL attenuates apoptosis 
To determine the relative contributions of KIT and ABL to GIST cell proliferation and survival 
we used the human GIST cell line GIST882 as a model (a generous gift of Dr. Jonathan Fletcher, 
Brigham and Women’s Hospital, Harvard Medical School, Boston, MA). The GIST882 cell line 
was derived from an imatinib-sensitive metastatic GIST and harbors a constitutively activating 
homozygous KIT mutation in exon 13 (K642E) [250, 251].  Following siRNA transfection cells 
were assayed with luminescent-based assays to determine cell viability or apoptosis.  As 
expected siRNA-mediated knockdown of KIT led to reduced cell proliferation and increased 
apoptosis in GIST882 cells. By contrast, siRNA against ABL showed little effect on GIST882 
proliferation or apoptosis. Interestingly, knockdown of both KIT and ABL led to reduced 
apoptosis of GIST882 cells when compared to KIT knockdown alone (Figure 39).  Proliferation 
was not changed when KIT and ABL were knocked down in combination compared to KIT 

























































Figure 39: Effects of siRNA-mediated knockdown of KIT and ABL1 on cell viability and apoptosis in 
GIST882 cells. 
Cells were transfected with siKIT and siABL alone or in combination (SMARTpool; Dharmacon, 
Lafayette, CO) using Amaxa nucleofection technology. Cellular proliferation (A) and apoptosis (B) were 
assessed 72 h and 48h post transfection respectively, using Cell-Titer-GLO and Caspase-GLO, respectively 
(Promega, Madison, WI). Cells were not treated with IM. 
 
B.4.3 Dual knockdown of both KIT and ABL does not affect BrdU incorporation of p27 
levels.   
After identifying that dual knockdown of KIT and ABL led to attenuated apoptosis in GIST882 
cancer cells we aimed to determine the effects of cell proliferation following single knockdown 
of KIT and ABL or dual knockdown of both.  48h hours after transient transfection of siRNA 
targeting ABL GIST882 cells showed BrdU incorporation levels on par with control (Figure 40).  
In contrast, BrdU incorporation was significantly reduced when either KIT or both KIT and ABL 
were knocked down (Figure 40). Levels of p27 following siRNA transfection showed a similar 
phenotype as BrdU incorporation.  p27 levels were greater following dual knockdown or KIT 
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knockdown alone, but were largely unchanged following single knockdown of ABL (Figure 41).  
These data confirm that loss of cell proliferation in GIST882 cells following dual siRNA 





Figure 40: Effects of siRNA-mediated knockdown of KIT and ABL1 on BrdU incorporation in GIST882 cells. 
Cells were transfected with siKIT and siABL alone or in combination (SMARTpool; Dharmacon, 
Lafayette, CO) using Amaxa nucleofection technology. BrdU incorporation was assessed 48h post 





Figure 41: Effects of siRNA-mediated knockdown of KIT and ABL1 on p27 levels in GIST882 cells. 
Cells were transfected with siKIT and siABL alone or in combination (SMARTpool; Dharmacon, 
Lafayette, CO) using Amaxa nucleofection technology. p27 levels were assessed 48h post transfection.  
Representative images and quantification shown.  300 cells per condition were counted.   
 
 
B.4.4 ABL Knockdown leads to increased AKT activity 
To determine the cause of apoptosis attenuation in KIT and ABL deficient cells, whole cell 
lysates were made 24, 48 and 72 h after siRNA transfection with KIT, ABL and combination of 
the two, then analyzed by immunoblotting for signaling mediators as well as regulators of the 
cell cycle and apoptosis (Figure 42). A non-coding scrambled siRNA served as negative control. 
KIT knockdown occurred within 24 h of transfection whereas sufficient knockdown of ABL was 
seen after 48 h in both single and combination experiments (Figure 42). As expected, knockdown 
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of KIT led to inhibition of downstream signaling (PI3K and MAPK pathways); as well as cell 
cycle arrest and apoptosis (data not shown). These effects were not present after knockdown of 
ABL. Unexpectedly, ABL knockdown led to a substantial increase in activated (AKT S473) and 
total AKT as well as increased S6K phosphorylation (Figure 42). To dissect the pathway leading 
to increased AKT activation after ABL knockdown, we analyzed the activation of signaling 
regulators upstream of AKT and found that PDK1 as well as PI3K phosphorylation increased 
(Figure 42). These effects were abolished when KIT was knocked down in combination with 




Figure 42: Effects of siRNA-mediated knockdown of KIT and ABL1 on downstream signaling as well as 
regulators of cell cycle and apoptosis in GIST882 cells. 
Immunoblot analysis of GIST882 cells at 24, 48 and 72 h after siRNA transfection as indicated. Cells 
were transfected with siKIT and siABL1 alone or in combination (SMARTpool, Dharmacon) using Amaxa 
nucleofection technology. Whole cell lysates were run on a 4-12% polyacrylamide gel. Actin is shown to 
demonstrate equal loading. C, control siRNA. Greater than 80% of KIT protein was absent after 24 h.  ABL 




Imatinib mesylate was initially engineered and FDA approved for the treatment of CML by 
inhibition of the BCR-ABL fusion protein.  However, it was soon found to be effective in other 
diseases including GIST.  Over a decade after being approved for metastatic GIST patients, 
Imatinib mesylate remains the first line therapy for more than half of GIST patients with 
unresectable or metastatic disease [182].  While initial response rates are very promising, nearly 
half of patients initially responsive to therapy will become resistant to it within 24 months of 
initial treatment [147].   While drug resistance due to acquired secondary mutations in KIT has 
been extensively published there still remain patients with inherent resistance for unknown 
reasons.  Having initially been FDA approved for another disease and protein target it is clear 
Imatinib mesylate has off target effects that need to be taken into account when dissecting its 
activity.   
We have outlined a molecular consequence of chronic imatinib mesylate treatment in 
GIST cancer cells due to off target suppression of ABL signaling.  Reduction in ABL signaling 
leads to increased signaling through the PI3K/AKT/mTOR proliferative pathway.  This would 
obviously be detrimental to both imatinib sensitive and resistant patients.  In the case of patients 
showing reduced drug efficacy imatinib might be doing more harm than good.  Our findings 
provide further evidence for the need to develop more specific inhibitors of KIT and its 
downstream targets for the long term treatment of patients with unresectable GIST.   
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APPENDIX C 
IDENTIFYING NEW THERAPEUTIC TARGETS IN GIST 
C.1 ABSTRACT 
Gastrointestinal stromal tumors (GISTs) are the most common mesenchymal tumors of the 
gastrointestinal tract.  They are caused by activating mutations in the KIT or platelet-derived 
growth factor receptor alpha (PDGFRA) receptor tyrosine kinase genes.  While most primary 
mutations can be effectively treated with small molecule kinase inhibitor imatinib mesylate 
(Gleevec®; Novartis Pharma, Basel, Switzerland); secondary mutations are resistant to such 
therapy.  Therefore new therapeutic options are urgently needed.   
The results of a small preliminary siRNA screen targeting kinases identified the SRC 
family kinase, LYN as having a role in GIST cell survival as measured by ATP based 
luminescent assay.  Further investigation confirmed loss of LYN leads to decreased BrdU 
incorporation and increased p27
Kip1
 expression.  Having provided proof of principle that kinases 
besides KIT play a role in GIST survival, proliferation and apoptosis we expanded our approach 
and performed a siRNA mediated screen encompassing all known kinases in the human genome 
(n=709).  This search was conducted with a siRNA library (Qiagen, Hilden, Germany) used in 
conjunction with a Cell Line 96-well Nucleofector Kit (Amaxa; Cologne, Germany).  Following 
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kinase transient knockout proliferation and apoptosis were determined using the CellTiter-Glo 
and Caspase-Glo luminescent assays, respectively.     All measurements were taken in triplicate 
and averaged.  A candidate was considered a hit when its siRNA-mediated knockdown led to a 
40% inhibition of cell proliferation when compared to control siRNA.  In the primary screen we 
identified 65 kinases that resulted in decreased cell proliferation when targeted by siRNA. These 
include several members of the PI3K and MAPK pathways such as PIK3R2 (phosphoinositide-3-
kinase, regulatory subunit 2), PIK3C2G (PI3K, class2, gamma polypeptide), MAP3K5 (mitogen-
activated protein kinase kinase kinase 5) and MAP2K4 (MAPK kinase 4).  Both pathways are 
known to actively regulate cell survival and cell proliferation signaling in GIST cells. Identifying 
members of these two pathways provides evidence of the efficacy of the screen.   Identification 
of additional therapeutic targets in imatinib-resistant GIST may prove valuable in the 
development of second generation small molecule inhibitors.   
C.2 BACKGROUND 
C.2.1 The SRC family kinase LYN 
Hypothesizing that kinases besides KIT and PDGFRA may function in GIST cell survival, 
proliferation and apoptosis we investigated the role of the SFK LYN in GIST.  SRC Family 
Kinases (SFKs) are human homologs of viral oncoproteins known to be involved in multiple 
signaling pathways controlling an array of networks regulating viability, metabolism, 
proliferation, migration and differentiation within many different cell lineages [252, 253].  Each 
SFK is about 60kD in molecular weight and has a common structure consisting of an N-terminal 
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unique domain, SH2 domain, SH3 domain and a tyrosine kinase domain (Figure 36) [254]. All 
SFKs show similar modes of regulation.   There are nine members of the SFKs that are further 
grouped into subfamilies: LYN related (LYN, HCK, LCK and BLK), SRC-related (SRC, YES, 
FYN and FGR) and FRK.  SFKs are frequently deregulated in cancer, in which they have been 
linked to tumor development and progression. The LYN gene is localized on human 
chromosome 8q13 and exists in two isoforms, p53 and p56 arising from alternate splicing of 
exon 2 with no functional differences between isoforms currently known [255].  LYN is an 
important component in cytokine signaling in a variety of cells but has predominately been 
characterized by its role in the regulation of growth and apoptosis of hematopoietic cells.   LYN 
is known to be involved in a positive feedback loop where it is phosphorylated by activated KIT 
and in turn phosphorylates KIT [225, 256].  Moreover, LYN has been shown to activate ABL 
[257] and play a role in imatinib-resistance in CML. Activation of LYN in CML cells results in 
upregulation of the anti-apoptotic protein BCL-2, and caspase-cleaved LYN has been shown to 
relocalize from the plasma membrane to the cytosol and protect CML cells from imatinib-
induced apoptosis [258, 259].  The role of LYN in KIT signaling as well as imatinib-resistant 
CML led us to hypothesize that LYN may play a role in GIST cell proliferation and apoptosis.   
C.2.2 Kinases as therapeutic targets 
Having shown proof-of-principle that kinases besides KIT and PDGFRA have important 
functions in GIST cell survival, proliferation and apoptosis we broadened our approach to all 
kinases within the human genome.  With roles in cell motility, proliferation, survival and 
apoptosis kinases are potential targets for future therapies.  The ATP binding pocket of kinases 
has been shown to be easily targeted by ATP-competitive inhibitors, a large number of which 
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have already been FDA-approved for the treatment of various malignancies [260-262].  The 
prototype example of this is imatinib mesylate in treatment of GIST and CML.  Furthermore, in 
recent years there has been development of both specific (i.e. GNF-2, GNF-5) and broad (i.e. 
nilotinib, sunitinib, erlotinib) small molecule kinase inhibitors.  Because imatinib resistance in 
GIST patients is often due to secondary mutations in the KIT or PDGFRA kinases, treating these 
tumors with second-line therapies targeting these receptors is problematic.  Identification of 
additional kinases involved in GIST cell proliferation and survival would allow for potentially 
new therapeutic targets.   
There are over seven hundred identified and predicted kinases in the human genome.  With 
such a large population of targets, high throughput screens are the preferred approach.  Small-
interfering RNA (siRNA) has been shown to be a powerful tool in eliciting cellular roles by 
targeting specific genes. Use of siRNA in a high-throughput manner will allow for efficient 
identification of kinases involved in GIST proliferation and apoptosis.  Identification of 
additional kinases that regulate GIST cell survival, proliferation and apoptosis will provide new 
therapeutic targets for tumors unresponsive to imatinib. In support of this, recent clinical trials 
have shown response to broader tyrosine kinase inhibitors in patients resistant to imatinib [226].  
We hypothesize that kinases besides KIT and PDGFRA play a role in GIST survival, 
proliferation and apoptosis.    
C.2.3 Significance 
Although 85% of patients benefit from the small kinase inhibitor, imatinib mesylate initially, 
more than 50% will develop drug resistance within two years of treatment.  Imatinib-resistance 
in GIST patients is usually due to secondary mutations in the KIT or PDGFRA kinase.  As a 
 141 
result of this, additional therapies targeting KIT or PDGFRA are problematic.  Since kinases are 
attractive “druggable” targets, identifying kinases other than KIT and PDGFRA that play a role 
in GIST cell proliferation and survival will open new avenues for the treatment of imatinib-
resistant GIST.     
C.3 MATERIALS AND METHODS 
C.3.1 Cell culture 
The imatinib-sensitive human GIST cell line GIST882 (kindly provided by Jonathan A. Fletcher, 
Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, USA) were derived 
from untreated metastatic GISTs and maintained in RPMI1640 (supplemented with 15% fetal 
bovine serum, FBS; 1% L-glutamine, 50 U/ml penicillin, 50 µg/ml streptomycin, 0.5 µg/ml 
amphotericin B). GIST882 cells carry a homozygous mutation in KIT exon 13 (K642E) (39).  
Imatinib-sensitive GIST-T1 cells (a generous gift of Dr. Takahiro Taguchi, Kochi Medical 
School, Kochi, Japan) were maintained in DMEM supplemented with 10% fetal bovine serum 
(FBS, Mediatech, Herndon, VA), 5 ml L-Glutamine, 50 U/ml penicillin (Cambrex, Walkersville, 
MD) and 50 µg/ml streptomycin (Cambrex) at 37°C/5% CO2.   Human chronic myeloid 
leukemia K562 cells were obtained from the American Type Culture Collection (Manassas, VA, 
USA) and maintained in the same manner as GIST882. 
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C.3.2 Transient transfection 
GIST882 cells were transfected with siRNA targeting a single kinase alone (Qiagen, Valencia, 
CA) or in combination (SMARTpool, Dharmacon) using Amaxa nucleofection technology as 
recommended by the manufacturer.  In vitro apoptosis and proliferation assays 
Apoptosis and cell viability studies were performed using the Caspase-Glo and CellTiter-Glo 
luminescence-based assays (Promega, Madison, WI, USA) as described previously (13). For 
these studies, cells were plated in a 96-well flat-bottomed plate (Perkin Elmer, San Jose, CA), 
cultured for 24 h and then incubated for 48 h (Caspase-Glo) or 72 h (CellTiter-Glo) with the 
respective compounds at indicated concentrations or DMSO-only solvent control. Luminescence 
was measured with a BioTek Synergy 2 Luminometer (BioTek, Winooski, VT), and the data 
were normalized to the DMSO-only control group.  
C.3.3 Immunoblot 
Protein lysates of GIST monolayer cultures (24) were prepared by washing twice with PBS and 
then scraping cells into RIPA buffer [1% NP40, 50 mmol/L Tris-HCl (pH 8.0), 100 mmol/L 
sodium fluoride, 30 mmol/L sodium pyrophosphate, 2 mmol/L sodium molybdate, 5 mmol/L 
EDTA, and 2 mmol/L sodium orthovanadate] containing protease inhibitors (10 μg/mL 
aprotinin, 10 μg/mL leupeptin, and 1 μmol/L phenylmethylsulfonyl fluoride). Whole cell lysates 
were then incubated for one hour with shaking at 4°C and then cleared by centrifugation for 30 
minutes at 14,000 rpm at 4°C. Protein concentrations were determined by the Bradford assay 
(Biorad, Hercules, CA). 25 µg of protein for each sample was separated on a 4-12% Bis-Tris gel 
and blotted onto a nitrocellulose membrane. 
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C.3.4 Statistical analysis 
Statistical significance was assessed using Student's t test for independent samples and the 
Mann-Whitney U test for not normally distributed samples (VassarStats, http://vassarstats.net). P 
values ≤0.05 were considered significant.  
 
C.4 RESULTS 
C.4.1 LYN is involved in GIST cell cycle regulation 
To test whether kinases other than KIT and PDGFRA play a role in GIST cell proliferation and 
survival we tested whether LYN could be involved.  LYN is a SFK that is involved in KIT 
downstream signaling and that has been shown to be upregulated in imatinib-resistant CML 
[257, 263, 264].  To test whether LYN plays a role in GIST we performed siRNA-mediated 
knockdown of LYN followed by luminescent assays in GIST882 cells (data not shown).  We 
then performed follow-up studies to illicit LYN’s role in GIST.  We have shown using siRNA-
mediated studies that LYN plays a role in both GIST proliferation and cell cycle progression 
(Figure 43).  Assaying for cell cycle arrest by staining for p27
Kip1
 levels following LYN 
knockdown showed a significant increase in cell cycle arrest (Figure 43A-B).  This trend of 
reduced cell proliferation was confirmed by BrdU incorporation following LYN knockdown 
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which showed a significant reduction in GIST882 cell proliferation similar to siRNA against KIT 
(Figure 43C-D).  These studies provide proof of principle that kinases besides KIT play a role in 




Figure 43: Effects of siRNA-mediated knockdown of KIT and LYN on p27
Kip1
 levels and BrdU incorporation 
in GIST882 cells. 
Cells were transfected with siKIT and siLYN alone (SMARTpool; Dharmacon, Lafayette, CO) using 
Amaxa nucleofection technology. p27 levels (A-B) and BrdU incorporation (C-D) were assessed 96h post 





Figure 44: Inhibition of LYN induces cell death in GIST882 cells. 
 (A)  Whole cell lysate protein levels of GIST882 cells following transient transfection of siRNA 
targeting KIT or LYN.  (B)  Whole cell lysate protein levels of GIST882 cells following treatment with an 
inhibitor of KIT (Imatinib) or LYN (Dasatinib).  Treatment concentrations and time are indicated.   
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C.4.2 Inhibition of LYN leads to increased cell death in GIST882 cells 
After identifying that LYN knockdown led to increased p27
Kip1
 levels and decreased BrdU 
incorporation we aimed to determine the effects of both LYN knockdown and a LYN inhibitor 
(Dasatinib) on GIST882 cell survival.   Transient knockdown of LYN by siRNA showed an 
increase in p27
Kip1
 levels 72 hours following transfection indication increased levels of cell cycle 
arrest (Figure 44).  In line with these results, inhibition of LYN by Dasatinib led to increased 
levels of PARP, γ-H2AX and H2AX 72 hours after treatment with dosages as low as 1 µM 
(Figure 44).    
 
C.4.3 Identification of additional kinases involved in GIST survival and/or proliferation 
Having shown proof-of-principle that other kinases besides KIT and PDGFRA play an important 
role in GIST cell survival we hypothesize that additional kinases may be involved in regulating 
cell viability and apoptosis in GIST. To determine this we broadened our initial screen to include 
all identified kinases in the human genome. A siRNA library containing 4 individual siRNA 
sequences (A-D) against all kinases (n=709; Qiagen) was used with Amaxa nucleofection.  In 
our initial validation studies a 30% reduction in cell proliferation was observed following KIT 
knockdown when compared to a non-coding scrambled siRNA control.  This figure served as the 
threshold for determining a “hit” kinase.  In the primary screen (sequence A) we identified 65 
kinases that resulted in decreased cell proliferation as determined above when targeted by siRNA 
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(Appendix A). These include several members of the PI3K and MAPK pathways such as 
PIK3R2 (phosphoinositide-3-kinase, regulatory subunit 2), PIK3C2G (PI3K, class2, gamma 
polypeptide), MAP3K5 (mitogen-activated protein kinase kinase kinase 5) and MAP2K4 
(MAPK kinase 4).  Both pathways are known to actively regulate cell survival and cell 
proliferation signaling in GIST cells. Identifying members of these two pathways provides 
credibility of the efficacy of the screen.  A secondary screen (sequence B) was performed to 
validate initial hits.  This screen narrowed the 65 hit kinases down to 37 (Table 5).  Of the 37 we 
further investigated a smaller subset of 10 kinases.  When targeted with siRNA, all ten candidate 
kinases decreased cell viability and increased apoptosis in GIST882 cells (Figure 45).  These 
kinases were chosen for previous evidence showing their role in disease.  Three of the ten hits we 
have chosen to further focus on include serine threonine kinase 33 (STK33), recently shown to 
play a role in KRAS dependent synthetic lethality in cancer cells [265-267], transforming growth 
factor beta receptor 1 (TGFBR1), shown to play a role in breast cancer and related to tyrosine 
receptor kinase (RYK), shown to play a role in Wnt signaling [268].  Further experiments will be 
performed to dissect the exact role these candidate kinase plays in GIST survival, proliferation 

















v-abl Abelson murine leukemia viral 
oncogene homolog 1 0.66 1.50 0.41 0.85 0.95 
ACVR1B activin A receptor, type IB 0.62 0.33 0.82 0.84 1.28 
ACVR2 activin A receptor, type II 0.63 1.14 1.28 0.97 1.40 
CSNK1A1 casein kinase 1, alpha 1 0.66 1.71 1.36 0.84 1.08 
CSNK1D casein kinase 1, delta 0.65 1.53 1.25 0.79 1.26 
CSNK2B casein kinase 2, beta polypeptide 0.60 2.13 1.65 0.95 1.07 
KDR 
kinase insert domain receptor (a 
type III receptor tyrosine kinase) 0.52 2.69 2.29 1.04 1.59 
KIT 
v-kit Hardy-Zuckerman 4 feline 
sarcoma viral oncogene homolog 0.64 1.92 1.02 0.63 0.67 
LYN 
v-yes-1 Yamaguchi sarcoma viral 
related oncogene homolog 0.54 0.89 0.46 0.87 1.46 
MAP3K5 
mitogen-activated protein kinase 
kinase kinase 5 0.50 0.59 1.42 0.92 1.19 
PIK3C2G 
phosphoinositide-3-kinase, class 2, 
gamma polypeptide 0.65 1.18 1.29 0.92 1.23 
PIK3R2 
phosphoinositide-3-kinase, 
regulatory subunit 2 (p85 beta) 0.39 2.17 1.88 1.05 1.45 
PRKAB2 
protein kinase, AMP-activated, beta 
2 non-catalytic subunit 0.27 1.89 2.06 0.79 1.50 
PRKACA 
protein kinase, cAMP-dependent, 
catalytic, alpha 0.24 2.79 1.71 0.96 1.31 
PRKACB 
protein kinase, cAMP-dependent, 
catalytic, beta 0.14 2.54 1.91 0.89 1.06 
PRKAR1B 
protein kinase, cAMP-dependent, 
regulatory, type I, beta 0.59 2.60 1.30 0.91 1.05 
PRKAR2A 
protein kinase, cAMP-dependent, 
regulatory, type II, alpha 0.51 0.54 0.71 0.61 1.43 
PRKG2 
protein kinase, cGMP-dependent, 
type II 0.59 1.03 1.13 0.88 1.40 
MAP2K7 
mitogen-activated protein kinase 
kinase 7 0.56 1.01 1.10 0.82 1.25 
PTK6 PTK6 protein tyrosine kinase 6 0.57 1.69 1.56 0.84 1.77 
GRK1 G protein-coupled receptor kinase 1 0.30 2.62 1.82 0.93 1.56 
ROCK1 
Rho-associated, coiled-coil 
containing protein kinase 1 0.35 2.43 2.01 0.87 1.35 
ROS1 
v-ros UR2 sarcoma virus oncogene 
homolog 1 (avian) 0.20 2.60 2.09 0.96 1.07 
RPS6KB1 
ribosomal protein S6 kinase, 70kDa, 
polypeptide 1 0.43 2.71 1.61 0.86 1.25 
RYK RYK receptor-like tyrosine kinase 0.46 0.68 0.57 0.81 1.04 
MAP2K4 
mitogen-activated protein kinase 
kinase 4 0.27 1.27 0.94 0.68 1.25 
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Table 5 continued 
SRC 
v-src sarcoma (Schmidt-Ruppin A-
2) viral oncogene homolog (avian) 0.40 1.04 1.06 0.85 1.02 
SRPK1 SFRS protein kinase 1 0.39 1.71 1.69 0.82 1.38 
SRPK2 SFRS protein kinase 2 0.41 1.94 1.72 0.90 1.10 
NEK4 
NIMA (never in mitosis gene a)-
related kinase 4 0.17 2.55 1.70 0.85 1.35 
STK10 serine/threonine kinase 10 0.29 2.57 1.58 0.72 1.09 
STK11 
serine/threonine kinase 11 (Peutz-
Jeghers syndrome) 0.44 2.37 1.28 0.67 0.74 
TGFBR1 
transforming growth factor, beta 
receptor I (activin A receptor type 
II-like kinase, 53kDa) 0.21 0.47 0.57 0.82 1.34 
TGFBR2 
transforming growth factor, beta 
receptor II (70/80kDa) 0.60 1.42 0.86 0.91 1.05 
TYK2 tyrosine kinase 2 0.27 1.93 1.15 0.93 1.07 
TYRO3 TYRO3 protein tyrosine kinase 0.63 1.49 1.50 0.77 1.26 
IKBKG 
inhibitor of kappa light polypeptide 
gene enhancer in B-cells, kinase 
gamma 0.61 1.69 1.89 0.80 1.22 
PDXK 
pyridoxal (pyridoxine, vitamin B6) 
kinase 0.37 2.16 1.67 0.80 1.15 
TNK1 tyrosine kinase, non-receptor, 1 0.43 3.19 1.37 0.98 0.95 
RIPK1 
receptor (TNFRSF)-interacting 
serine-threonine kinase 1 0.27 2.60 1.55 0.75 1.08 
AKAP4 A kinase (PRKA) anchor protein 4 0.21 0.59 0.90 0.85 1.41 
STK19 serine/threonine kinase 19 0.57 1.17 0.80 0.94 1.10 
STK29 serine/threonine kinase 29 0.09 1.92 1.40 0.93 0.91 
MAP3K7IP2 
mitogen-activated protein kinase 
kinase kinase 7 interacting protein 2 0.55 1.74 2.11 0.99 1.29 
MAST2 
microtubule associated 
serine/threonine kinase 2 0.22 2.22 1.87 0.85 1.27 
EPS8L1 EPS8-like 1 0.32 1.96 1.70 0.72 1.04 
ETNK2 ethanolamine kinase 2 0.56 2.84 1.45 0.92 1.17 
PI4K2B 
phosphatidylinositol 4-kinase type-
II beta 0.23 2.25 1.50 0.98 0.97 
PAK6 p21(CDKN1A)-activated kinase 6 0.32 0.42 0.75 0.64 1.40 
TAOK1 TAO kinase 1 0.31 0.85 0.97 0.79 1.15 
CERK ceramide kinase 0.35 1.88 1.01 1.02 1.06 
STK33 serine/threonine kinase 33 0.24 1.40 1.24 0.90 1.11 
Sharpin shank-interacting protein-like 1 0.45 1.69 1.79 0.75 1.09 
BRSK1 BR serine/threonine kinase 1 0.18 1.92 1.66 0.78 1.10 
NYD-SP25 protein kinase NYD-SP25 0.34 2.34 1.54 0.80 1.07 
LYK5 protein kinase LYK5 0.32 1.54 1.33 0.63 0.97 
LMTK3 lemur tyrosine kinase 3 0.36 0.43 0.75 0.71 1.24 
DCAMKL2 doublecortin and CaM kinase-like 2 0.39 0.64 0.80 0.87 1.02 
ERK8 
extracellular signal-regulated kinase 
8 0.60 1.25 0.79 0.92 0.87 
CDKL4 cyclin-dependent kinase-like 4 0.58 0.84 1.16 0.73 1.12 
SBK1 SH3-binding domain kinase 1 0.59 0.96 1.28 0.68 1.11 
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Table 5 continued 
LOC391295 
similar to spermiogenesis associated 
serine/threonine kinase 22D; 
serine/threonine kinase FKSG81; 
spermiogenesis associated 4 0.24 1.20 1.49 0.73 1.26 
LOC391533 
similar to Vascular endothelial 
growth factor receptor 1 precursor 
(VEGFR-1) (Vascular permeability 
factor receptor) (Tyrosine-protein 
kinase receptor FLT) (Flt-1) 
(Tyrosine-protein kinase FRT) 
(Fms-like tyrosine kinase 1) 0.24 1.39 1.44 0.72 0.96 
LOC392265 
similar to Cell division protein 
kinase 5 (Tau protein kinase II 
catalytic subunit) (TPKII catalytic 
subunit) (Serine/threonine-protein 
kinase PSSALRE) 0.58 1.16 1.11 0.59 1.07 
  Below or very close to KIT control           
  
Within 1 standard deviation of KIT 
control           
  
Within 3 standard deviation of KIT 
control           






Figure 45: Transient knockdown of 10 hits leads to increased cell death. 
Cells were transfected with indicated siRNA using Amaxa nucleofection technology. Cellular 
proliferation (ATP) and apoptosis (Caspase-7/9) were assessed 72 h and 48h post transfection respectively, 




Surgical intervention remains the first line of therapy in newly diagnosed GIST patients.  In the 
case of patients with unresectable or metastatic disease where surgical intervention is not an 
option, Imatinib mesylate is the first line of therapy.  [182].  While initial response rates are very 
promising, nearly half of patients initially responsive to therapy will become resistant to it within 
24 months of initial treatment due to secondary mutations in KIT [147].   In light of this we 
aimed to determine if inhibition of other kinases besides KIT could result in GIST cell death.  
Following a small preliminary siRNA based screen we identified the SRC family kinase, LYN as 
a potential therapeutic target.  Inhibition of LYN led to reduced cell proliferation and increased 
cell death levels comparable to KIT inhibition when measured by ATP and caspases based 
luminescence assays respectively.  Furthermore, reduced cell proliferation and increased cell 
cycle arrest were confirmed by reduced BrdU incorporation and increased p27
Kip1
 expression 
respectively.    Further studies on the role of LYN in GIST cell survival and proliferation will 
need to be conducted to determine its potential as a therapeutic target.  
Following identification of a kinase besides KIT being involved in GIST cell survival and 
proliferation we aimed to expand our search of new druggable targets by performing a siRNA 
screen of the entire human kinome. The preliminary screen produced 65 hits, which were 
verified and reduced to 37 hits through a secondary screen using alternative siRNA sequences.  
These 37 hits were then reduced to 10 and follow up experiments were performed.  The 
treatment of Imatinib-resistant GIST patients has proven difficult, resulting in abysmal 5-year 
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survival rates [269].  Identifying potential new therapeutic targets will aid in development of new 
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